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Abstract 
 
The global epidemic of obesity poses serious burden to human health due to its associated risks of 
chronic diseases including type 2 diabetes and cardiovascular diseases. Adipose tissues have received 
a lot of attention since as it has become clear that adipocytes and macrophages in them are important 
integrators of diverse physiological pathways regulating systemic insulin sensitivity and energy 
homeostasis. It is therefore urgently necessary to identify regulatory convergence points that can be 
therapeutic targets to improve insulin resistance and impaired energy homeostasis in obesity. 
Tonicity responsive enhancer-binding protein (TonEBP), also known as NFAT5, is a critical regulator 
in cellular adaptation to hypertonic stress, macrophage activation, and T-cell development. In this study 
I found that adipocyte TONEBP expression correlated with body mass index in subcutaneous fat tissues 
from human subjects. In addition, TONEBP expression in leukocytes correlated with fasting blood 
glucose in patients with type 2 diabetes. In subcutaneous adipose tissues of mice TonEBP expression 
increased >50-fold in response to feeding with high fat diet (HFD). In order to understand the role of 
TonEBP in obesity, I examined a line of mice with TonEBP haplo-deficiency. These animals showed 
resistance to HFD-induced weight gain and insulin resistance in association with higher energy 
expenditure and lower adipose tissue inflammation. To delineate TonEBP action mechanisms in adipose 
tissues, I studied the role of TonEBP in both adipocytes and macrophages further. 
In order to investigate the role of TonEBP in macrophages, a line of mice with myeloid-specific 
deletion of TonEBP was generated. When fed with HFD, these animals displayed improved insulin 
resistance without changes in body weight. Their adipose tissue contained fewer M1 macrophages and 
more M2 macrophages indicating reduced inflammation. Lipopolysaccharide (LPS)-induced assembly 
of NFκB enhanceosome was found. In this enhanceosome, TonEBP was required for the recruitment of 
p300 and RNA polymerase II. TonEBP was rate-limiting in that increased expression of TonEBP 
enhanced the NFκB activity and reduced TonEBP expression lowered it without affecting NFκB itself. 
LPS induced the expression of TonEBP leading to elevated assembly of the NFκB enhanceosome. 
Recombinant TonEBP molecules incapable of recruiting p300 did not stimulate NFκB. A natural small 
molecule cerulenin was found to specifically disrupt the enhanceosome assembly without altering 
NFκB. Cerulenin dramatically suppressed the inflammatory activation of macrophages and prevented 
death by septic shock. Thus, the TonEBP-mediated NFκB enhanceosome offers a promising target for 
useful anti-inflammatory agents. In addition, TonEBP deficiency promoted M2 macrophage 
polarization with enhanced PPARγ expression. These data suggest that variations in the level of TonEBP 
expression determine individual variations in insulin resistance and inflammation regulated by NFκB 
and PPARγ. Taken together the findings reveal that TonEBP promotes insulin resistance through the 
stimulation of NFκB in combination with the suppression of PPARγ. 
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To address the role of TonEBP in adipocytes, another line of mice with adipocyte-specific deletion 
of TonEBP was produced. When fed with HFD these animals displayed improved insulin resistance and 
lower body weight much like the TonEBP haplo-deficient animals. They also showed elevated energy 
expenditure and resistance to hypothermia when exposed to cold. In subcutaneous white adipose tissues 
(WAT) higher levels of beige fat markers and thermogenic genes such as uncoupling protein-1 (UCP-
1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) were expressed. 
This was due to an enhanced expression of the β3-adrenergic receptor (Adrb3). TonEBP recruited DNA 
methyltransferase 1 (DNMT1) to the Adrb3 promoter and promoted DNA methylation leading to the 
suppression of the promoter. These data indicate that TonEBP in adipocytes promotes obesity and 
insulin resistance by the suppression of the Adrb3 expression and blocking the beiging of WAT.  
In conclusion, TonEBP in adipocytes and macrophages contributes to obesity and insulin resistance 
due to the suppression of WAT beiging and the promotion of inflammation, respectively. As such, 
TonEBP offers an attractive therapeutic target for obesity and type 2 diabetes. 
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Chapter1. Background 
 
1-1. Obesity and its related metabolic disorders 
Obesity is epidemic in the worldwide, with rapidly and steadily rising rates. Obesity and related 
diseases are the biggest threats to human health in the world. Obesity is associated with complex 
metabolic disorders such as certain types of cancer, type 2 diabetes, non-alcoholic fatty liver, 
dyslipidemia, hypertension, cardiovascular disease and stroke [1-3]. In addition, obese people of all 
ages are often psychological and social problems, such as low self-esteem and depression. According 
to World Health Organization (WHO) analysis, overweight and obesity are linked to more deaths 
worldwide than underweight. The deaths are caused by 44% of diabetes, 23% of ischemic heart disease 
and 7-41% of certain cancers [4]. Many studies suggested that obesity might be causative factors for 
these complications by several mechanisms (Fig. 1-1) [5].  
 
1-2. Adipose tissue inflammation in obesity 
One of the most reliable links between obesity and its complication is inflammation. Obesity induces 
low-grade inflammation in metabolic tissues including adipose tissue, liver and skeletal muscle. 
Obesity-induced inflammation causes systemic insulin resistance by inhibiting insulin signal 
transduction in metabolic tissues (Fig. 1-2) [6]. Abdominal adipose tissue inflammation is mainly 
occurred and it is a central mediator for systemic insulin resistance in obese condition. The imbalance 
between energy intake and outputs causes large amounts of lipid accumulation in adipocytes, leading 
to white adipose tissue expansion in the processes such as adipose tissue hyperplasia and hypertrophy. 
In this adipose tissue expansion, several adipocytes located in a region at a distance from the blood 
vessel undergo hypoxia and necrosis leading to secretion of chemokines for immune cell infiltration. 
After that, they are surrounded by immune cells initiating a local inflammatory responses characterized 
by an enhanced Tumor necrosis factor-α (TNF-α) and leptin levels, and reduced Interleukin-10 (IL-10) 
and adiponectin levels (Fig. 1-3) [7-8]. Stressful conditions such as hypoxia induce adipocyte 
dysfunction and reduced insulin action in adipocytes with apoptosis.  
 
1-3. Adipose tissue macrophages (ATMs)  
In adipose tissue and other metabolic tissues, macrophage has an important role in metabolic 
functions. The number and polarization of adipose tissue macrophages (ATMs) actively cross-talk with 
adipocytes in adipose tissue and reflect the metabolic profiles. For example, in lean mice, ATMs have 
alternatively activated (M2) phenotype comprising about 10% of stromal vascular cells (SVCs). 
However, classically activated (M1) macrophages are infiltrated to about 50% of SVCs and ATMs are 
polarized from M2 type to M1 type in obese mice [9]. The population of M1 and M2 ATMs is important 
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to determine the level of inflammatory and metabolic states in adipose tissue of obesity (Fig. 1-3). The 
M1 macrophages infiltrated by obesity secrete pro-inflammatory cytokines such as TNFα and promote 
insulin resistance in adipose tissue. M1 activation and pro-inflammatory responses are mainly promoted 
by transcriptional factor nuclear factor ĸB (NFĸB). However, M2 macrophages enhances insulin 
sensitivity of adipocytes by secreting anti-inflammatory cytokines such as IL-10 and this polarization 
is enhanced by peroxisome proliferator-activated receptor γ1 (PPARγ1) (Fig. 1-4) [10]. Therefore, 
macrophage polarization in adipose tissue is critical for the development of insulin resistance in obesity. 
 
1-4. Beiging of white adipose tissue (WAT)  
Adipocytes are classically divided into white adipose tissue (WAT), which stores energy by 
accumulating lipids, and brown adipose tissue (BAT), which controls energy expenditure through 
nonshivering thermogenesis. Recently, a new type of brown-like adipose tissue was discovered in 
human that are called ‘beige’ and ‘brite’ from brown in white [11] (Fig. 1-5). The three types of 
adipocyte have many distinct characteristics associated with different colors, morphology, localization, 
cell composition (lipid droplet, mitochondria content) and gene expression [12]. WAT is either ivory or 
yellow due to unilocular/large lipid droplets with few mitochondria and stores excess energy as 
triglycerides to regulate energy homeostasis.  
Brown adipocyte has different phenotypes including brownish color with high amount of 
mitochondria and multilocular small lipid droplets and regulates thermogenesis which is important for 
human in cold environment [13]. The thermogenesis process in brown adipocyte is mainly activated by 
uncoupling protein-1 (UCP1) in mitochondria. UCP1 mediates regulated proton leak across the 
mitochondrial inner membrane and thus dissipate the proton electrochemical gradient built up by 
converting chemical energy into the heat [14]. BAT is mainly localized in paravertebral, suprarenal, 
supraclavicular regions. In human, BAT generally represents in large depots during infancy but, only 
small amounts of BAT are remained in adults [11].  
Beige adipocyte has combined features of white and brown adipocyte. Beige adipocytes are 
differentiated from beige precursor or trans-differentiated from white adipocyte in white adipose tissues 
[14]. Specific WAT depots can develop high numbers of beige adipocytes (beiging) induced by cold 
exposure, exercise, PPARγ ligands and β3-adrenergic agonists [15]. The beiging of WAT induced by 
stimuli makes healthy metabolic profiles with enhanced energy expenditure. However, excess energy 
intake and thermoneutrality increase lipid storage in adipocytes that morphologically resemble classic 
white adipocytes (whitening) [15]. The whitening of adipose tissue causes adipocyte dysfunction, 
inflammation and impaired thermogenesis leading to obesity and type 2 diabetes. (Fig. 1-6) 
In this obese state, the increased number or activity of beige adipocytes by stimuli improves 
metabolic disorders and prevents obesity through the enhanced energy expenditure. Thus, there has 
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been emerging interest in “beiging” as a platform for anti-obesity therapeutic approaches. 
 
 
1-5. Tonicity-responsive enhancer binding protein (TonEBP) 
TonEBP, also known as nuclear factor of activated T cells 5 (NFAT5), belongs to the Rel family of 
transcriptional factors including NFκB and NFAT1-4 [16, 17] (Fig. 1-7). TonEBP has a variety of 
molecular and physiological functions. TonEBP was initially identified as the central DNA binding 
transcription factor of cellular response to hypertonic stress by regulating genes such as BGT1, SMIT, 
AR and HSP70 [16, 18-20] (Fig. 1-8).  
Recent studies have revealed that TonEBP act as a transcriptional co-activator in activation of NFĸB 
and it promotes the M1 activation of macrophages and pro-inflammatory responses [21-22]. 
Consequently, TonEBP haplo-deficiency is associated with reduced inflammation leading to prevention 
of inflammatory and autoimmune diseases including diabetic nephropathy [23], diabetic retinopathy 
[24], rheumatoid arthritis [25], atherosclerosis [26] and encephalomyelitis [27] and seizure [28] in 
mouse models (Fig. 1-9).  
The more recent study showed that TonEBP inhibits adipogenesis through the suppression of PPARγ2 
expression, suggesting that TonEBP is one of the key transcription factors that control adipogenesis 
[29]. In this regulation, TonEBP is a transcriptional co-suppressor in PPARγ2 transcription by recruiting 
histone methyltransferase to the promoter.  
These studies demonstrated that TonEBP has pleiotropic functions including DNA binding 
transcription factor, transcriptional co-activator and transcriptional co-repressor in inflammation and 
adipocyte differentiation. Inflammation and adipocyte differentiation is critical for obesity and type 2 
diabetes development. However, the role of TonEBP in obesity and type 2 diabetes was uncovered.  
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Figure 1-1. Obesity and its related complications 
Nature Reviews Drug Discovery 9; 107-115 (2010) 
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Figure 1-2. Obesity-induced inflammation and insulin resistance 
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Figure 1-3. Inflammation and immune cells in obese adipose tissue 
Nature Reviews Immunology 11; 85-97 (2011) 
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Figure 1-4. Crosstalk between macrophages and adipocytes in adipose tissue 
Annu Rev Physiol 72 ; 219-246 (2010) 
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Figure 1-5. Three types of adipocytes: Brown, Beige and White adipocyte 
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Figure 1-6. Adipose tissue beiging and metabolic health 
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Figure 1-7. Scheme of NFATs and NFĸB structure 
Int J Biochem Cell Biol 36 ; 1166-1169 (2004) 
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Figure 1-8. Physiology of TonEBP in hypertonic stress 
Physiology 24 ; 186 (2009) 
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Figure 1-9. TonEBP in inflammatory diseases 
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Chapter2. Macrophage TonEBP promotes inflammation and insulin 
resistance by regulating M1/M2 polarization 
 
2-1. Introduction 
 
Type 2 diabetes is a major public health problem in worldwide with rising incidence. Type 2 diabetes 
characterized by hyperglycemia induces many complications including diabetic nephropathy, diabetic 
retinopathy, heart disease and hypertension. Obesity is a major causative factor for type 2 diabetes by 
inducing insulin resistance. Adipose tissue macrophages (ATMs) are critical regulators that link obesity 
with insulin resistance and type 2 diabetes. The number and polarization of ATMs actively cross-talk 
with adipocytes in adipose tissue and reflect the metabolic profiles. In lean mice, adipose tissue have 
alternatively activated resident macrophages comprising about 10% of stromal vascular cells (SVCs). 
However, M1 macrophages are infiltrated to about 50% of SVCs and ATMs are polarized from M2 type 
to classically activated (M1) type in obese mice [1]. The population of M1 and M2 ATMs is important 
to determine the level of inflammatory and metabolic states in adipose tissue of obesity. The M1 
macrophages infiltrated by obesity secrete pro-inflammatory cytokines such as TNFα and promote 
insulin resistance in adipose tissue. M1 activation and pro-inflammatory responses are mainly promoted 
by transcriptional factor nuclear factor ĸB (NFĸB). However, M2 macrophages enhances insulin 
sensitivity of adipocytes by secreting anti-inflammatory cytokines such as IL-10 and this polarization 
is enhanced by peroxisome proliferator-activated receptor γ1 (PPARγ1) [2].  
NFκB transcription factor regulates the expression of several hundred cellular genes involved in a 
variety of cellular and physiological processes, such as immune and inflammatory responses, 
developmental processes, cellular growth, and apoptosis [3-4]. The key regulatory event in the 
activation of the p65:p50 heterodimeric NFκB is the phosphorylation of IκB proteins by the IκB kinase 
complex, which leads to IκB protein ubiquitination and subsequent degradation [4-5]. Removal of IκB 
leads to the release of cytoplasmic p65:p50 heterodimer, which then moves into the nucleus, associates 
with transcriptional cofactors p300 and CREB binding protein (CBP), and drives the expression of 
target genes. Recent studies have shown that DNA bound NFκB initiates the formation of distinct 
enhanceosomes in a target gene-specific manner [6-9]. NFκB is persistently active in a number of 
human diseases, including cancer, arthritis, chronic inflammation, asthma, neurodegenerative diseases, 
type2 diabetes, and heart disease [10-12], and thus, effective and safe inhibitors of NFκB would have 
wide-ranging therapeutic use.  
Tonicity-responsive enhancer binding protein (TonEBP), also known as nuclear factor of activated T 
cells 5 (NFAT5), belongs to the Rel family of transcriptional factors which include NFκB and NFAT 
[13-14]. TonEBP was initially identified as the central regulator of cellular response to hypertonic stress 
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[13, 15-17]. Recent studies have demonstrated that TonEBP is involved in the M1 activation of 
macrophages by promoting the expression of pro-inflammatory genes in response to TLR4 activation 
[18-19]. TonEBP haplo-deficiency is associated with dramatically reduced inflammation and pathology 
in mouse models of rheumatoid arthritis [20] and atherosclerosis [21]. 
In order to understand molecular basis of the TonEBP function in inflammation and insulin resistance, 
we investigated TonEBP action in the M1 and M2 macrophage polarization. Here, we find that TonEBP 
is required for the recruitment of p300 to NFĸB in M1 macrophage activation. In addition, we find that 
cerulenin is a powerful inhibitor of NFκB with minimal toxicity due to disruption of the p300 
recruitment to NFκB without affecting its nuclear localization or phosphorylation. Thus, TonEBP is an 
essential component of the lipopolysaccharide (LPS)-induced NFκB enhanceosome critical for 
expression of pro-inflammatory genes. In M2 macrophage polarization, TonEBP represses M2 
polarization through the suppression of PPARγ1 expression in macrophages. In myeloid specific 
TonEBP deficient mice fed with high fat diet (HFD), they showed improved insulin resistance without 
changes in body weight. Their adipose tissue has lower M1 and higher M2 macrophage population 
indicating lower inflammatory responses. These findings uncover the functions of macrophage TonEBP 
to promote insulin resistance through the regulations of NFκB activity and PPARγ1 expression. 
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2-2. Materials and methods 
 
Animals 
All the methods involving live mice were carried out in accordance with the approved guidelines. 
All experimental protocols were approved by Institutional Animal Care and Use Committee of the 
Ulsan National Institute of Science and Technology (UNISTACUC-12-15-A).  
Mice carrying the loxP-targeted TonEBP gene (TonEBPfl/fl) were reported previously [22]. 
Transgenic mice expressing Cre recombinase under the control of either the myeloid-specific 
lysozyme M (LysM) promoter were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). 
TonEBPfl/fl and LysM-cre mice crossed to yield mice with specific targeted deletion of TonEBP in 
macrophages (TonEBPfl/fl, LysM-cre).  
For septic shock, TonEBPfl/fl, LysM-cre mice and their TonEBPfl/fl littermates were intraperitoneally 
injected with D-galactosamine (700 mg/kg; Sigma Aldrich) plus LPS (150 μg/kg; Sigma Aldrich). 
After injection, animals were monitored for 16 h for survival. 
For obese mice model, mice at 8 weeks age were fed with high fat diet (60% fat by kcal) or normal-
chow diet (10% fat by kcal) during 9-16 weeks.  
 
Cells and reagents  
Macrophage cell line RAW264.7 cells, mouse embryo fibroblasts (MEFs), COS-7 cells and 
HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal 
bovine serum (FBS; Thermo fisher scientific Inc, Waltham, MA, USA) and penicillin/streptomycin 
(100U/ml and 100μg/ml; GE healthcare life sciences, Logan, UT, USA). RAW264.7 cells were 
passaged by scraping with a rubber policeman and MEFs, COS-7 cells and HEK293 cells were 
passaged using trypsin/EDTA (Invitrogen, Carlsbad, CA, USA). Peritoneal macrophages derived from 
TonEBPfl/fl and TonEBPfl/fl, LysM-cre mice were cultured in RPMI containing 10% fetal bovine serum, 
penicillin/streptomycin (100 U/ml and 100 μg/ml). Cells were maintained at 37°C in incubator with 
5% CO2. Cells were pretreated with cerulenin, BAY 11-7082 and β-lapachone (Sigma Aldrich, USA) 
for 1h and exposed to lipopolysaccharide (LPS; Sigma Aldrich) or Interleukin-4 (IL-4; R&D Systems, 
Minneapolis, MN, USA). Anti-p65, RelB, c-Rel and p52 antibodies from NFκB family sample kit 
(4776, Cell Signaling Technologies, Berkeley, CA, USA), anti-p50 (sc8414, SantaCruz 
Biotechnology, Santa Cruz, CA, USA City), ser 276 phosphorylated p65 (sc101749, SantaCruz 
Biotechnology), p300 (sc584, SantaCruz Biotechnology) and LaminB (sc6217, SantaCruz 
Biotechnology) antibodies, anti-Hsc70 (200-301-A28, Rockland, Gilbertsville, PA, USA) and anti-
TonEBP antibody [13] were used for immunoblotting. 
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Cells were transfected with lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). All siRNA 
duplexes were purchased from Integrated DNA Technologies (Coralville, IA, USA) and used for 
siRNA-mediated knockdown. For overexpression, RAW264.7 cells were infected with the empty 
control virus (Ad-EV) or the adenovirus carrying the human TONEBP gene (Ad-TONEBP). 
 
Isolation of the human primary monocytes and differentiation of monocyte-derived 
macrophages. 
The study was approved by the Institutional Review Board of the Ulsan National Institute of 
Science and Technology (UNISTIRB-15-25-A). Human blood was provided by the Korea 
Gynecologic Cancer Bank through Bio & Medical Technology Development Program of the MSIP, 
Korea. Mononuclear cells were isolated from heparinized blood using Histopaque-1077 (Sigma-
Aldrich, St. Louis, MO, USA), according to the manufacturer’s instructions. Monocytes were further 
purified using CD14 microbead positive selection and MACS separation columns (Miltenyi Biotec, 
Bergisch, Germany), according to the manufacturer’s instructions. The macrophages were obtained 
after 7 days culture of human monocytes in RPMI-1640 medium supplemented with 10% FBS, 1% 
sodium pyruvate, 0.1% β -mercaptoethanol and human M-CSF (20 ng/ml; Miltenyi Biotec). 
 
Flow cytometry analysis 
Stromal vascular cells (SVCs) were isolated from epididymal white adipose tissue obtained from 
mice fed high fat diet during 4 weeks. Epididymal white adipose tissue were minced in FACS buffer 
(PBS + 1% bovine serum albumin) containing 1mg/ml type II collagenase. They were incubated at 
37˚C with shaking for 1 hr. After incubation, 10 ml of DMEM/F12 were added and they were 
centrifuged at 500g for 15 min. SVCs were incubated with 5ml of RBC lysis buffer (Sigma) for 5 min 
at room temperature and then they were filtered with a 40μm filter after addition of 10ml of 
DMEM/F12. After centrifugation at 500g for 5 min, SVCs were resuspended in FACS buffer and 
incubated with Fc Block (BD Biosciences) for 10 min at 4 °C before staining primary antibodies for 
30 min at 4 °C. PE-F4/80, PerCP-CD11b, FITC-CD11c and Alexa fluor 647-CD206 FACS antibodies 
are purchased from BD Biosciences. Cells were gently washed twice and resuspended in FACS buffer. 
After gating of F4/80 and CD11b positive cells, they were analyzed by CD11c and CD206 using a 
FLSRFortessa flow cytometer (BD Biosciences). Unstained and single stained cells were used for 
setting compensation and gates.  
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Metabolic analysis 
Fasting blood glucose, body weight and food intake were measured weekly, Mice were given an 
orally injection of D-glucose (2 g/kg body weight) after overnight starvation for the glucose tolerance 
test (GTT) and were intra- peritoneally injected with insulin (0.75U/kg body weight) for insulin 
tolerance test (ITT). Serum glucose levels were determined in tail blood samples using a glucometer. 
Body temperatures were measured using a digital thermometer (TD-300; Shibaura Electronics, Tokyo, 
Japan). 
 
Immunoblot assay 
Cell were washed two times with cold PBS and lysed in RIPA buffer (0.01M Tris, pH7.4, 0.15M 
NaCl, 0.001M EDTA, 0.001M EGTA, 1% Triton X-100, 0.002M PMSF and protease inhibitor 
(roche)). After centrifugation of lysate, supernatant was used for immunoblot assay. Protein 
concentration was measured by BCA protein assay system (Pierce, Rockford, IL, USA). Equal 
amounts of protein from each sample were separated by SDS-PAGE and immunoblotted using 
specific primary antibodies. HRP-conjugated mouse, rabbit and goat secondary antibodies were used 
for detection. The antigen-antibody binding was detected by enhanced chemiluminescence Western 
blotting detection reagents (GE healthcare life sciences).  
 
RNA isolation and real-time PCR  
 Total RNA was isolated using the TRIzol reagent (Invitrogen) according to the manufacturer's 
instructions. cDNA was synthesized by M-MLV reverse transcriptase (Promega, Madison, WI, USA). 
After reverse transcription, real time PCR was performed using SYBR Green I Master and 
LightCycler 480 II (Roche, Rotkreuz, Switzerland). Measured cycle threshold (Ct) values were 
normalized with cyclophilin A and they were expressed as fold-over control samples. 
 
Immunohistocytochemistry  
 The cells were grown on glass coverslips and fixed with 4% paraformaldehyde in PBS (pH 7.4) for 
20 min at 4°C. Cells were permeabilized with 0.3% Triton-X 100 in PBS for 30 min and blocked with 
PBS containing 3% goat serum and 1% bovine serum albumin for 1 h at room temperature. After 
incubation with rabbit anti-TonEBP and rabbit anti-p65 overnight at 4°C, the cells were washed with 
PBS and treated with goat anti-mouse or anti-rabbit Alexa Fluor 488-conjugated and Alexa Fluor 594-
conjugated secondary antibodies for 1 h. Cells were washed with PBS and incubated in 0.1 μg/ml 
Hochest (DAPI) for 30 min. After wash with PBS, coverslips were mounted onto microscope slides. 
Images were recorded using an Olympus FV1000 confocal fluorescence microscope.  
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Immunoprecipitation assay 
  Cell lysates (10-500μg) were prepared using RIPA buffer in a tube on ice. Antibody (1-5μg) was 
added to cell lysate and they were incubated for overnight at 4°C under rotary agitation. 40μl of 
protein A/G agarose beads (GE healthcare) was added and incubated for 2 hr at 4°C under rotary 
agitation. The bead-antibody-antigen complex was spin downed by centrifugation at 4°C for 1min and 
removed supernatant. The complex was washed for 10 min by RIPA buffer at 4°C and it was repeated 
with three times. After wash, 40μl of sample buffer was added and boiled at 95°C for 5min and 
centrifugated with top speed for 1min at room temperature. The samples were transferred to new tube 
and analyzed by immunoblotting.  
 
Nuclear and cytoplasmic fractionation  
  Cells were harvested by using scrapper and centrifugation at 500 g. The cell pellet was washed by 
suspension with PBS. The cell nucleus and cytoplasm were separated by using Nuclear and 
Cytoplasmic extraction kit (Pierce) according to manufacturer’s instruction. Nuclear fraction was 
confirmed by Lamin B. 
 
Electromobility shift assay   
Electrophoretic mobility shift assay (EMSA) was performed using Lightshift Chemiluminescent 
EMSA kit (Pierce). 5 μg of nuclear extracts were incubated with poly(dI:dC), binding buffer and 5’ 
biotinylated DNA (5’- AAACAGGGGGCTTTCCCTCCTC -3’ for NFκB binding site on TNFα 
promoter, N1; 5’-GCTCCGTGGAAAACTCACTTGG-3’ for putative TonEBP binding site, T1; 5’- 
TGTCCCCAACTTTCCAAACCCT-3’ for T2; 5’-ACCAAGGAAGTTTTCCGAGGGTT-3’ for T3;  
5’-TCATAATGGAAAATTCCATGCCA-3’ for T0) at room temperature for 20 min. Samples were 
separated by electrophoresis for 4 h in 4% (40% 29:1 acrylamide/bis solution) gel for TonEBP and 8% 
gel for p65. The detection was performed according to manufacturer’s instructions. 
 
Chromatin immunoprecipitation assay  
  Cells were grown in 10 cm diameter culture dishes and with LPS when indicated. Fixation was 
performed with 1% formaldehyde at room temperature for 10 min. The fixation was stopped with 
0.125 M glycine for 5 min at room temperature. After three washes with cold PBS, cells were 
collected and lysed in 1 ml of SDS lysis buffer (1% SDS, 10 mM EDTA and 50 mM Tris-HCl pH 8.1) 
for 10 min on ice. Cell lysates were sonicated (Bioruptor KRB-01, BMS, Tokyo, Japan) for six cycles 
of 20 s on plus 30 s off with constant frequency and maximum intensity to obtain DNA fragments 
between 400 and 1,000 bp. Each sample was diluted 10× in dilution buffer (0.01% SDS, 1.1 % Triton 
X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1 and 167 mM NaCl) for immunoprecipitation. 
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Samples were pre-cleared with protein A Sepharose beads (Millipore, Bedford, MA, USA) that were 
previously pre-adsorbed with salmon sperm DNA for 1 h at 4°C. Specific antibodies were added after 
removing the pre-clearing beads: anti-p65 IgG, and normal rabbit IgG (Abcam, Cambridge, UK), anit-
TonEBP serum, and normal rabbit serum (Merck millipore, Darmstadt, Germany). After adding 
antibodies, the lysates were incubated overnight at 4°C. Protein A Sepharose beads were then added, 
incubated for 2 h at 4°C, and then washed with low salt washing buffer (0.1% SDS, 1% Triton X-100, 
20 mM Tris-HCl pH 8.1, 2 mM EDTA, and 10 mM NaCl), high salt washing buffer (0.1% SDS, 1% 
Triton X-100, 20 mM Tris-HCl pH 8.1, 2 mM EDTA and 500 mM NaCl), LiCl washing buffer (0.25 
M LiCl, 1% NP-40, 1% deoxycholic acid, 1 mM EDTA and 10 mM Tris-HCl pH 8.1) and twice with 
final washing buffer (10 mM Tris-HCl pH 8.0 and 1 mM EDTA). To elute the DNA, beads were 
incubated with elution buffer (1% SDS and 100 mM NaHCO3) for 20 min at 65 °C. To reverse the 
cross-linking, samples were incubated overnight at 65°C 200 mM NaCl, 30 min at 37°C with 50 
μg/ml RNase (Pierce) and 2 hr at 45°C with 100 μg/ml proteinase K. DNA was purified using the 
QIAGEN PCR purification system. DNA was then subjected to RT-qPCR using primers; 5’-
CCCAACTCTCAAGCTGCTCT-3’ and 5’- CTTCTGAAAGCTGGGTGCAT-3’ for TNFα promoter. 
Immunoprecipitated DNA from each sample was normalized to its respective chromatin input. 
 
DNA affinity purification assay  
Cells were lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.5% Triton-100). 
1mg of extracts were diluted with binding buffer (4 mM Tris-HCl pH 7.5, 20 mM HEPES pH 7.5, 5% 
glycerol, 170 mM NaCl, 0.5 mM EDTA, 1 mM MgCl2 and 0.1 % Triton X-100) and incubated 
overnight with 5’ end biotinylated DNA probe (30 nM) containing a κB site or putative TonE site of 
mouse TNF-α promoter. They were mixed for 2 hr with 50 μl of streptavidin-coated agarose beads, 
and protease inhibitors (Roche). Beads were pelleted, washed two times with TE buffer with 100 mM 
NaCl, two times with binding buffer, once with PBS and then resuspended in 50 μl of Laemmli 
sample buffer. Precipitated proteins were separated by 7% SDS-PAGE and immunoblotted for 
TonEBP and p65. 
 
Luciferase assay  
  Cells were transfected with either a TonE-driven Photinus luciferase plasmid or a κB-driven 
luciferase plasmid in pGL4.74 (hRluc/TK, Promega). The Renilla luciferase reporter plasmid (pRL-
TK, Promega) was used as a control for transfection efficiency. Luciferase activity after 8 h of 
stimulation was measured using the Dual-Luciferase Assay System (Promega) according to the 
manufacturer’s instructions. Luciferase activity was normalized by activity of renilla luciferase. 
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Cytokine production  
 TNFα in supernatants from LPS-stimulated cells or serum samples from D-Galactosamine 
(GalN)/LPS-injected mice were analyzed by ELISA using a commercial kit (R&D Systems, 
Minneapolis, MN, USA). 
 
Statistical analysis  
Data are presented as means + s.d. or +s.e.m Statistical significance (p < 0.05) was estimated by 
student’s t-test. All statistics was performed with GraphPad Prism 5.0 software (GraphPad, San Diego, 
CA, USA). 
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2-3. Results 
 
2-3-1. TonEBP promotes macrophage M1 activation and sepsis  
Macrophage activation is a hallmark of inflammation, and NFκB is a central regulator of pro-
inflammatory macrophage activation (M1 macrophage) [23]. In order to explore the role of TonEBP in 
macrophage activation, we obtained a line of mice with myeloid-specific deletion of the TonEBP gene 
by crossing the line in which the exon 4 of the TonEBP gene was flanked by lox P sequences (TonEBPfl 
allele) [22] with the line expressing the cre recombinase in myeloid cells using the promoter of the 
lysozyme 2 gene (LysM-cre) [24]. Peritoneal macrophages (PECs) prepared from TonEBPfl/fl, LysM-cre 
mice showed a dramatically reduced TonEBP mRNA expression compared to those prepared from their 
TonEBPfl/fl littermates (Fig. 2-1a). TonEBP mRNA expression in other tissues such as liver and brain 
was normal consistent with myeloid-specific deletion of the TonEBP gene (data not shown). When 
stimulated with LPS, PECs from the TonEBPfl/fl, LysM-cre mice showed significantly reduced 
expression of NFκB-dependent pro-inflammatory genes TNFα and iNOS (Fig. 2-1a), and NO 
production (Fig. 2-1b) in response to LPS. In response to D-galactosamine and LPS administration, 
which was used to produce a mouse model of sepsis [25], the rise in serum TNFα levels were reduced 
by ~40% in the TonEBPfl/fl, LysM-cre mice compared to their TonEBPfl/fl littermates (Fig. 2-1c). 
Furthermore, severity of sepsis measured by ensuing death was reduced in the TonEBPfl/fl, LysM-cre 
animals (Fig. 2-1d). These data show that myeloid-specific deletion of the TonEBP gene results in 
blunted macrophage activation and septic shock in association with inflammatory responses. 
 
2-3-2. TonEBP binds to the TNFα promoter without direct interaction with DNA 
In macrophages, TonEBP is induced by Toll-like receptor engagement and activates many genes by 
direct binding to their promoters including that of TNFα [18]. Fig. 2-2a shows a schematic 
representation of 1.6 kb upstream of the mouse TNFα gene where three putative binding sites for 
TonEBP (T1, T2, and T3) and a putative NFκB binding site (N1) are located. In order to understand 
molecular action of TonEBP, we first examined the affinity of TonEBP and NFκB to the sites using 
electrophoretic mobility shift assay (EMSA) of nuclear extracts prepared from RAW264.7 macrophage 
cell line. The N1 probe detected several prominent bands which showed up after LPS stimulation (Fig. 
2-2b). All of these bands were competed away by excess cold probe, but only the top two bands were 
supershifted by p65 antibody but not by TonEBP antiserum indicating that they represented p65-
containing NFκB molecules. These data demonstrate that N1 is a functional κB sequence and p65-
containing NFκB molecules have specific affinity to N1. 
The macrophage nuclear extracts displayed specific binding to a tonicity-responsive enhancer (TonE) 
sequence (T0) which was enhanced by hypertonicity, supershifted by TonEBP antiserum, and competed 
33 
 
away by excess cold probe demonstrating that the band represented DNA-bound TonEBP molecules 
(Fig. 2-2c). On the other hand, none of the putative TonEBP binding sequences T1, T2, and T3 displayed 
binding to the band, and were unable to compete with T0 for TonEBP binding. Thus, T1, T2, and T3 
are not a functional TonE and TonEBP does not have high affinity for the DNA sequence in the promoter 
region. 
We next performed chromatin immunoprecipitation (ChIP) to investigate NFκB and TonEBP 
interaction to the promoter in situ. p65 bound to the N1 region in LPS-dependent manner (Fig. 2-2d) as 
expected from the EMSA data above. Surprisingly, TonEBP also displayed LPS-dependent binding to 
the region. Since TonEBP did not have affinity to the sequence in the region, we asked whether there 
was a protein-protein interaction between TonEBP and p65. To address this question, we performed 
DNA affinity purification analysis (DAPA) of the cell lysates using a biotin-labeled N1 probe. Both 
NFκB and TonEBP displayed LPS-dependent binding to the N1 probe (Fig. 2-2e) suggesting that there 
is a protein-protein interaction between them. 
 
2-3-3. TonEBP interacts with p65 through Rel-homology domains (RHDs) 
Molecular basis of the TonEBP-p65 interaction was investigated. Co-immunoprecipitation 
experiments revealed that both endogenous proteins (Fig. 2-3a) and over-expressed proteins (Fig. 2-3b) 
could be mutually pulled down by each other. In order to map sites of interaction, we produced various 
recombinant proteins of TONEBP and p65 (Fig. 2-4). Analyses of the recombinant proteins suggest that 
the RHDs are critical for both. TONEBP constructs without RHD – TONEBP ΔRHD and YC1 ΔRHD 
– did not show interaction with p65, while those of intact RHD such as YC1 and partial RHD such as 
TONEBP ΔIPT did (Fig. 2-4a). In addition, protein product of a mutant TonEBP allele lacking the N-
terminal half of RHD did not bind p65 (see below). Likewise, p65 constructs with its RHD domain 
partially deleted (p65 ΔIPT and p65 ΔRHD-n) did not interact with TONEBP (Fig. 2-4b). 
 
2-3-4. TonEBP stimulates NFκB activity independent of DNA binding 
In HEK293 cells, over-expression of TONEBP resulted in a stimulation of both κB-driven and TonE-
driven luciferase (Fig. 2-5a), and expression of NFκB- and TONEBP-target genes (Fig. 2-5b) as 
expected. On the other hand, TONEBP ΔRHD, which did not interact with p65 (Fig. 2-4a) and could 
not bind DNA [26], did not stimulate neither κB-driven nor TonE-driven gene expression (Fig. 2-5). 
TONEBP ΔIPT lacks the dimerization domain and does not bind DNA [26]. Interestingly, TONEBP 
ΔIPT retained its ability to interact with p65 (Fig. 2-4a) and stimulated κB-driven gene expression but 
not TonE-driven gene expression (Fig. 2-5). These observations demonstrate that TonEBP stimulates 
NFκB independent of DNA binding. 
The mouse TonEBP Δ allele was created by deletion of exon 6 and 7 [17]. The deletion results in an 
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in-frame deletion of 128 amino acids in the N-terminal portion of RDH as depicted in Fig. 2-6a. 
Interestingly, mouse embryonic fibroblast (MEF) cells established from TonEBPΔ/Δ mice showed 
reduced κB-driven luciferase expression both in basal conditions and after LPS stimulation (Fig. 2-6b). 
Expression of NFκB-target genes TNFα and IκBα in response to LPS was also reduced in these cells 
(Fig. 2-6c) consistent with reduced NFκB activity. We investigated molecular basis for the reduced 
NFκB activity. The TonEBPΔ/Δ MEF cells expressed the TonEBP Δ protein which migrated faster than 
the wild type TonEBP protein (Fig. 2-6d). In these cells, expression of the NFκB subunits – p65, RelB, 
c-Rel, p52, and p50 – was normal. Nuclear localization of p65 and TonEBP in response to LPS looked 
normal (Fig. 2-6e). In addition, serine 276 phosphorylation of p65 in response to LPS was normal in 
the TonEBPΔ/Δ MEF cells (Fig. 2-6f). Finally, we asked whether reduced TonEBP expression affected 
DNA binding of p65. Knock-down of TonEBP did not affect DNA binding of p65 based on EMSA and 
DAPA (Fig. 2-7). Thus, NFκB activity was reduced in the TonEBPΔ/Δ MEF cells despite normal 
expression of NFκB subunits, nuclear translocation, phosphorylation, and DNA binding of p65 in 
response to LPS. The reduced NFκB activity can be explained by the inability of the mutant protein to 
interact with p65 (Fig. 2-8a) providing further support to the notion that TonEBP stimulates NFκB 
independent of DNA binding, i.e, via protein-protein interaction. 
 
2-3-5. TonEBP is required for the recruitment co-activator p300 to NFκB: LPS-induced NFκB 
enhanceosome 
We asked how the TonEBP-p65 interaction led to stimulation of the NFκB activity. Two possibilities 
were explored. One was recruitment of the large and powerful transactivation domain (TAD) of TonEBP 
[27]. To test this, we generated a fusion protein of p65 and the TAD. The fusion protein displayed a 
markedly elevated transcriptional activity which was gradually reduced as the TAD domain was serially 
deleted from the C-terminus (Fig. 2-9a, b) as reported earlier [27]. This observation suggests that the 
TAD of TonEBP enhance transactivation by p65 bound to DNA. On the other hand, over-expression of 
Yc1 (see Fig. 2-4a), which was expected to compete away TAD-containing TonEBP and reduce 
transactivation of NFκB, did not inhibit NFκB (Fig. 2-9c) suggesting that there should be other 
pathways of transactivation by TonEBP. 
We explored the possibility that TonEBP was involved in the recruitment of transcriptional co-
activators such as p300. p300 is an acetyltransferase involved in p65 acetylation which is essential in 
the assembly of NFκB enhanceosome [28]. When p65 was immunoprecipitated, both TonEBP and p300 
were also brought down (Fig. 2-8a) suggesting that the all the three molecules were in a complex. The 
interaction increased in response to LPS (Fig. 2-8a) in correlation with increased nuclear localization 
of p65 (Fig. 2-6e). Of note, the TonEBP Δ protein did not interact with p65 and, thereby, the amount of 
p300 brought down with p65 was dramatically lower in the TonEBPΔ/Δ MEF cells (Fig. 2-8a, 2nd and 
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4th lane). The inability of the TonEBP Δ protein to interact with p65 and recruit p300 explains the 
reduced NFκB activity in the TonEBPΔ/Δ MEF cells (Fig. 2-6b). These data indicate that the TonEBP-
p65 interaction was critical for the recruitment of p300 to p65. This was further supported by the 
observation that increased expression of p300 did not lead to increased κB-driven luciferase expression 
in the TonEBPΔ/Δ MEF cells (Fig. 2-8b). Thus, the inability of the TonEBP Δ protein to transactivate 
NFκB was due to its inability to interact with p65, i.e., inability to form the NFκB enhanceosome.  
The TonEBP containing enhanceosome complex was characterized further. Knockdown of p300 led 
to reduced recruitment of both p300 and TonEBP to p65 (Fig. 2-10a), while knockdown of p65 did not 
affect the association between p300 and TonEBP (Fig. 2-10b). These observations suggest that 
preformed TonEBP-p300 heterodimer is recruited to p65 after its nuclear translocation in response to 
LPS. Knockdown of TonEBP led to reduced p300 recruitment to p65 (Fig. 2-10c), as expected. Of note, 
ChIP experiments revealed that the LPS-dependent assembly of NFκB enhanceosome on the promoter 
of the TNFα promoter, as measured by recruitment of p65, Sp1 and Pol II to the N1 site [29-30], was 
reduced after TonEBP knockdown (Fig. 2-11). Thus, TonEBP deficiency is associated with not only 
lower recruitment of p300 to p65 but also reduced assembly of the NFκB enhanceosome on the 
promoter leading to lower NFκB activity observed under these conditions. 
 
2-3-6. Cerulenin disrupts the p65-TonEBP-p300 interaction and inhibits NFκB without toxicity 
From a screening of natural compounds for inhibition of NFκB, we discovered that cerulenin, an 
inhibitor of fatty acid synthase [31], disrupted the p65-TonEBP-p300 interaction. Cerulenin reduced co-
precipitation of TonEBP and p300 in p65 immunoprecipitation assays both under basal conditions and 
after LPS treatment (Fig. 2-12a).  
We characterized cerulenin action in molecular detail. Cerulenin inhibited NO production in response 
to LPS in a dose-dependent manner without compromising cell viability (Fig. 2-12b). The lack of 
cytotoxicity by cerulenin contrasts with BAY11-7082, a protein kinase inhibitor: while both compounds 
inhibited NO production with comparative efficacy, cerulenin displayed no detectible toxicity unlike 
BAY11-7082 which displayed a dose-dependent decrease in viability (Fig. 2-13). The reduced NO 
production was associated with reduced NFκB activity based on reduced κB-driven luciferase 
expression (Fig. 2-12c) and reduced expression of NFκB-target genes (Fig. 2-12d) and their proteins 
(Fig. 2-12e). As expected, cerulenin potently inhibited systemic inflammation and septic death (Fig. 2-
14). Of great interest, the reduced NFκB activity was not associated with changes in the nuclear 
localization, DNA binding, or phosphorylation of p65 (Fig. 2-15). Taken together, the data provide 
compelling evidence that cerulenin prevents inflammation by inhibiting NFκB as it specifically disrupts 
the p65-TonEBP-p300 interaction. As such, cerulenin displayed lower, if any, toxicity compared to 
BAY11-7082 blocking of the nuclear localization. 
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2-3-7 TonEBP suppresses M2 phenotype 
Given the role of TonEBP in M1 gene expression and inflammatory diseases (see above), we explored 
the role of TonEBP in M2 macrophage polarization in response M1 (LPS) and M2 stimuli (IL-4). While 
LPS increased TonEBP expression, as previously described [18], we found that IL-4 reduced TonEBP 
expression (Fig. 2-16a) in mouse RAW264.7 macrophages. Time course experiments revealed that 
significant increase in TonEBP mRNA expression was reached in 3 h in response to LPS and the 
expression continued to rise to 12 h (Fig. 2-16b). In contrast, treatment with IL-4 caused significant and 
gradual reduction in TonEBP mRNA expression 3–12 h later (Fig. 2-16b). Thus, M2 signal reduced 
TonEBP expression while M1 signal promoted it. During M1 polarization of macrophages in response 
to LPS, anti-inflammatory M2 genes including IL-10 are induced to provide a negative feedback [32-
33]. We investigated whether TonEBP knockdown using siRNA-mediated gene silencing would 
influence the expression of M2 phenotype in M1 polarized macrophages. TonEBP knockdown in 
RAW264.7 cells enhanced mRNA expression of M2 genes such as IL-10, arginase-1 (Arg1), mannose 
receptor (CD206) and IL-4 receptor α (IL-4Rα) both in unstimulated and LPS-stimulated cells (Fig. 2-
16c). We next asked whether TonEBP regulates expression of M2 genes in M2-polarized macrophages. 
TonEBP knockdown increased the expression of Arg-1, CD206 and IL-10 genes upon IL-4 stimulation 
(Fig. 2-16c). Reversely, TonEBP overexpression led to reduced mRNA expression of M2 genes in both 
M1 and M2 polarized macrophages (Fig. 2-16d), demonstrating that TonEBP directly suppresses M2 
phenotype in both M1 and M2 macrophages. 
 
2-3-8 TonEBP suppresses IL-10 and its signaling in M1 macrophages.  
Among the M2 genes suppressed by TonEBP, we were interested in IL-10 because it is an essential 
anti-inflammatory cytokine, capable of reducing pro-inflammatory mediators and inducing M2 
phenotype in macrophages [34-36]. We found that IL-10 secretion (Fig. 2-17a) and mRNA expression 
(Fig. 2-16 and 2-17b) were higher in cells whose TonEBP was knocked down under basal conditions, 
and they increased steadily over time after stimulation with LPS. Because IL-10 leads to increase in 
expression of anti-inflammatory regulators such as suppressor of cytokine signaling-3 (SOCS3) [37], 
IL-4Rα [38] and Bcl-3 [39] through signal transducer and activator of transcription 3 (STAT3) [40], we 
asked whether TonEBP affected the activation of STAT3 and expression of STAT3-inducible genes in 
RAW264.7 cells. In line with the increased secretion of IL-10, TonEBP knockdown augmented STAT3 
phosphorylation in response to LPS (Fig. 2-17c) and enhanced LPS-induced expression of SOCS3 (Fig. 
2-17c) and mRNA for IL-4Rα , SOCS3 and Bcl-3 (Fig. 2-17d). In order to confirm the regulation of IL-
10 by TonEBP in vivo, we examined peritoneal macrophages (PM) and bone marrow derived 
macrophages (BMDM) obtained from the TonEBP+/Δ mice displaying TonEBP haplodeficiency [17]. 
Both PM’s and BMDM’s from the TonEBP+/Δ mice showed reduced TonEBP expression, both in 
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unstimulated and LPS-stimulated conditions (Fig. 2-17e), and enhanced IL-10 mRNA expression 
compared to those from TonEBP+/+ littermates (Fig. 2-17f). We asked whether the suppression of IL-
10 and its signaling by TONEBP was also present in human macrophages. To answer the question, we 
obtained primary monocytes from three donors. Macrophages differentiated from the monocytes 
responded to LPS by increasing the expression of TONEBP, IL-10, and anti-inflammatory regulators 
like RAW264.7 cells (Fig. 2-18). In addition, expression of the IL-10 and anti-inflammatory regulators 
was enhanced under basal and LPS-stimulated conditions in response to TONEBP knockdown. These 
data demonstrate that TONEBP suppresses IL-10 expression and M2 phenotype both in human and 
mouse macrophages. 
 
2-3-9. β-Lapachone, a chemotherapeutic agent, suppresses TonEBP expression and enhances IL-
10 expression.  
We screened a commercial library of natural compounds (BioMol, Plymouth Meeting, PA, USA) to 
find small molecules that suppressed TonEBP expression. Because TonEBP is essential for the 
expression of inducible nitric oxide synthase (iNOS) in LSP-stimulated macrophages [18], we 
monitored LPS-dependent nitric oxide production using the Griess reaction. Among the compounds 
that reduced the nitric oxide production, we found that β-lapachone, which has a variety of 
pharmacological effects including anti-inflammatory, anti-cancer and anti-angiogenic actions [41-43], 
suppressed TonEBP expression both under LPS stimulation and hypertonicity (Fig. 2-19a). As expected 
from the reduced TonEBP expression, β-lapachone increased the mRNA expression of IL-10 and CD206 
whereas suppressed the mRNA levels of COX-2 and iNOS in response to LPS (Fig. 2-19b). β-Lapachone 
also suppressed mRNA expression of tonicity-responsive TonEBP target genes such as 
sodium/chloride/betaine cotransporter (BGT-1) and sodium/myo-inositol cotransporter (SMIT) (Fig. 2-
19c). The data provide strong evidence that the effects of β-lapachone on IL-10 expression is due to the 
reduction of TonEBP expression. 
 
2-3-10. TonEBP suppresses M2 macrophage polarization through the reduction of PPARγ1 
expression 
We found that TonEBP regulates not only NFκB-induced M1 activation but M2 polarization. We 
demonstrated that M1 macrophage activation is mediated by NFĸB enhanceosome consisting of NFĸB, 
TonEBP and p300. Next, we investigated mechanism of M2 macrophage polarization by TonEBP 
deficiency in macrophages. M2 macrophages are polarized by several transcription factors such as 
C/EBPβ, PPARγ1 and STAT6 [23]. It is already published that TonEBP suppresses PPARγ expression 
in adipocytes leading to inhibition of adipogenesis [46]. We confirmed the increased expression of 
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PPARγ1 without changes in phosphorylation and expression of STAT6 and expression of C/EBPβ in 
TonEBP knockdowned RAW264.7 cells (Fig. 2-20a). TonEBP deficient macrophages also have 
enhanced PPARγ1 and CD36, PPARγ target gene, mRNA expressions (Fig. 2-20b). These data 
demonstrated that TonEBP suppresses M2 macrophage polarization through the inhibition of PPARγ 
expression in macrophages.  
 
2-3-11. Myeloid specific TonEBP deficient mice protect from obesity-induced insulin resistance in 
obese mice 
The population of M1 and M2 ATMs is important to determine the level of inflammatory and 
metabolic states in adipose tissue of obesity. The M1 macrophages infiltrated by obesity secrete pro-
inflammatory cytokines such as TNFα and promote insulin resistance in adipose tissue. However, M2 
macrophages enhances insulin sensitivity of adipocytes by secreting anti-inflammatory cytokines such 
as IL-10 [2]. Inflammatory regulators such as NFkB simultaneously increase M1 and M2 activation in 
macrophages. Therefore, common anti-inflammatory drugs reduce M1 activation but also M2 activation. 
However, TonEBP increases M1 but suppresses M2, so when it is deficient, M1 activation decreases 
and M2 activation increases. Therefore, TonEBP inhibition might be more efficient for improvement of 
insulin resistance in obesity. 
To examine the role of macrophage TonEBP on obesity-induced impaired glucose homeostasis, we 
generated myeloid-specific KO mice. WT or myeloid specific TonEBP KO mice were fed a HFD for 
22 weeks. Interestingly, the myeloid specific TonEBP KO mice showed a similar weight gain compared 
to WT mice (Fig. 2-21a). Food intake was similar between groups (data not shown). However, the 
myeloid specific TonEBP KO mice protected against obesity-induced glucose intolerance and insulin 
resistance (Fig. 2-21b-d). Obesity causes fatty liver and it causes liver damage, but myeloid specific 
TonEBP KO revealed protection from liver damage showing lower AST and ALT concentration in 
serum (Fig. 2-21e). These phenotypes called obese but metabolically healthy were explained by reduced 
immune cell infiltration to eWAT, pro-inflammatory responses (M1 activation) in eWAT and liver (Fig. 
2-22a-c). In this eWAT, myeloid specific TonEBP KO showed not only reduced pro-inflammatory gene 
but enhanced anti-inflammatory gene expression, M2 macrophage markers (IL10, Ym1, Mgl1 and 
CD206) and transcription factor (PPARγ1) (Fig. 2-22d). Consistent with mRNA expression of M1 and 
M2 markers, we found that myeloid specific TonEBP KO mice have more M2 macrophage population 
(F4/80+ CD11b+ CD11C- CD206+) with less M1 macrophages (F4/80+ CD11b+ CD11C+ CD206-) in 
eWAT (Fig. 2-22e-f).  
To find the association of TonEBP with diabetes in humans, we isolated blood leukocytes from non-
diabetic or diabetic human. In human blood monocytes, TonEBP mRNA expression was correlated with 
blood glucose (Fig. 2-22g). We conclude that macrophage TonEBP promotes insulin resistance by 
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suppressing M2 macrophage polarization and promoting M1 macrophage polarization. These data 
suggest that targeted downregulation of macrophage TonEBP may be a good therapy for alleviating 
inflammation-associated metabolic syndrome. 
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2-4. Discussion 
 
TonEBP was originally identified based on its specific DNA binding to the tonicity-responsive 
enhancer (TonE) [13]. In vivo footprinting analyses revealed that DNA binding of TonEBP to the TonE 
sites in the promoter regions of its target genes temporally correlated with transcriptional stimulation in 
response to hypertonicity [44-45]. ChIP experiments have shown that the induction of TNFα in response 
to LPS is associated with TonEBP recruitment to its promoter (Fig. 2-2) [18]. The data presented here 
demonstrate that the recruitment is independent of DNA binding. Rather, TonEBP is recruited through 
a protein-protein interaction with NFκB. We recently reported analogous DNA binding-independent 
recruitment of TonEBP to the promoter of the PPARγ gene in association with the suppression of the 
promoter [46]. The histone acetyl transferase activity of p300 is critical for the formation of NFκB 
enhanceosome [47]: After recruitment to p65 bound to DNA, p300 acetylates histones leading to 
opening/remodeling of chromatin and binding of proximal factors such as Sp1 and RNA polymerase II. 
The data presented here are consistent with this model in that TonEBP deficiency results in not only 
reduced recruitment of p300 to the TNFα promoter but also other components of the NFκB 
enhanceosome such as Sp1 and RNA polymerase II. Thus, TonEBP-dependent recruitment of p300 is a 
key early step in the formation of NFκB enhanceosome. 
NFκB-mediated inflammation is involved in the pathogenesis of a wide range of diseases including 
cancer [5], metabolic and vascular disease [11], and even viral infection [48]. Much of the anti-
inflammatory activity of the widely used glucocorticoids is due to blockage of NFκB activity [49]. 
Genetic and pharmacological inhibition of NFκB reverses insulin resistance in animal models [50]. A 
recent clinical trial showed that salicylate, which inhibits NFκB, improved glycemia in patients with 
type 2 diabetes and decreased inflammatory mediators [51]. Effective inhibitors of NFκB with minimal 
side effects would be quite useful for therapeutic use against the diverse inflammatory diseases. 
Obesity-associated tissue inflammation is now recognized as a major cause of insulin resistance. IL-
10 and M2 macrophage can inhibit the deleterious effects of pro-inflammatory cytokines on insulin 
signaling [2]. Notably, loss of M2 macrophage exacerbates expression of inflammatory markers within 
the liver and adipose tissue [1-2] and is not always compensated by inhibition of pathologic 
inflammatory phenotype alone, demonstrating that the action of M2 macrophage is limited to inhibition 
of pro-inflammatory molecules in tissue inflammation. Thus, suppression of M1 activation in 
combination with promotion of M2 activation is desirable as a therapeutic strategy against inflammatory 
diseases. Here, myeloid specific TonEBP deficient mice have suppression of M1 activation with 
promotion of M2 activation in adipose tissue. This polarization of macrophages improves metabolic 
profiles in obese mice without changes in body weight. As such, TonEBP should be an attractive target 
for obesity-associated insulin resistance and inflammation. 
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Figure 2-1. Reduced inflammation and septic death in mice with myeloid-specific deletion of the 
TonEBP gene 
(a) Peritoneal macrophages (PECs) isolated from TonEBP fl/fl, LysM-cre (solid bars) and their TonEBP 
fl/fl littermates (open bars) were stimulated for 6 h with LPS or vehicle (V). mRNA expression for 
TonEBP, TNFα and iNOS was measured by RT Q-PCR. (b) PECs were treated for 24 h with LPS or 
vehicle (V). Nitrite was measured using Griess reagent from the media. (c) TonEBP fl/fl, LysM-cre mice 
(solid bars) and their TonEBP fl/fl littermates (open bars) were intraperitoneally injected with D-
galactosamine (700 mg/kg) plus LPS (150 μg/kg) (GalN/LPS) or vehicle (V). After 1 h, TNFα was 
measured using ELISA from serum samples. (d) TonEBP fl/fl, LysM-cre (red line) and their TonEBP fl/fl 
littermates (blue line) were intraperitoneally injected with GalN/LPS. The animals were monitored for 
16 h for survival. n = 15. Data (mean + s.e.m., n = 4-5) are representative of three independent 
experiments. *P < 0.05 compared to TonEBP fl/fl, LysM-cre. 
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Figure 2-2. TonEBP binds to the κB site of the TNFα promoter without direct interaction with 
DNA 
(a) Schematic representation of putative binding sites of TonEBP (T1, T2, T3) and NFκB (N1) in the 
TNFα promoter region. The DNA sequences for putative binding sites were described in 
electromobility shift assay in Methods. (b) Nuclear extracts were prepared from RAW264.7 cells 
stimulated for 1 h with LPS (100ng/ml) or vehicle (V). EMSA was performed using the nuclear 
extracts and biotin-labeled N1 probe. Where indicated, anti-p65 IgG (p65) or normal IgG (IgG) was 
added to supershift p65-DNA complex; and-TonEBP serum (TonEBP) or normal rabbit serum 
(Serum) to supershift TonEBP-DNA complex. In the last lane, 50 times concentration of unlabeled N1 
was added for competition. (c) Nuclear extracts were prepared from RAW264.7 cells cultured for 24 h 
in hypertonic medium containing extra 75 mM NaCl (NaCl) or control, isotonic medium (-). EMSA 
was performed using the nuclear extracts and biotin-labeled probes: T0 (positive control for TonEBP 
binding), T1, T2, and T3. Anti-TonEBP antibody and normal rabbit serum were used to supershift 
TonEBP-DNA complex. In the last 4 lanes, 50 times concentration of unlabeled probe was added for 
competition. (d) RAW264.7 cells were treated for 1 h with LPS or vehicle (V). ChIP was performed 
using normal rabbit serum, anti-TonEBP serum, normal IgG, and anti-p65 IgG. The precipitates were 
quantified for the N1 region using Q-PCR. A representative set of four independent sets of 
experiments is shown. (e) Cell extracts were prepared from RAW264.7 cells treated for 1 h with LPS 
or vehicle (V). Biotin-labeled N1 probe was used to perform DAPA. DAPA samples and cell lysates 
were immunoblotted for TonEBP and p65. Images of immunoblots are shown on the left, and intensity 
ratios of TonEBP and p65 in DAPA/cell lysate are plotted on the right. A representative set of four 
independent sets of experiments is shown.  
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Figure 2-3. TonEBP interacts with p65 
(a) MEF cell lysates were immunoprecipitated (IP) with normal IgG or anti-p65 IgG (left), or normal 
serum or anti-TonEBP serum (right). The immunoprecipitates and cell lysates were immunoblotted for 
TonEBP and p65 as indicated. (b) COS-7 cells were co-transfected with Myc-p65 and Flag-TonEBP. 
Cell lysates were immunoprecipitated with normal IgG or anti-Myc IgG (left), or anti-Flag IgG 
(right). The immunoprecipitates and cell lysates were immunoblotted for TonEBP, Myc, or Flag as 
indicated. A representative set of three independent sets of experiments is shown.  
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Figure 2-4. TonEBP interacts with p65 via respective RHDs.  
(a) Schematic representation of human TONEBP and its recombinant fragments. RHD, Rel-homology 
domain; RHD-n, N-terminal subdomain of RHD involved in DNA contact; IPT, Ig-like, plexins, 
transcription factors domain with an immunoglobin-like fold involved in dimer formation. COS-7 
cells were cotransfected for 24 h with Flag-p65 plus Myc-tagged TONEBP or one of the recombinant 
TONEBP fragments shown. Cell lysates were immunoprecipitated (IP) with anti-Myc antibody.  
(b) Schematic representation of p65 and its fragments. COS-7 cells were cotransfected for 24 h with 
Myc-YC1 plus Flag-tagged p65 or one of its fragments shown. Cell lysates were immunoprecipitated 
with anti-Flag antibody. A representative set of two independent sets of experiments is shown.  
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Figure 2-5. Stimulation of NFκB by TonEBP requires the TonEBP-p65 interaction 
(a) COS-7 cells were transfected with increasing amount of Myc-tagged TONEBP, TONEBPΔIPT 
(ΔIPT) or TONEBPΔRHD (ΔRHD) along with κB-luciferase or TonE-luciferase reporter construct. 
Cells were stimulated for 6 hours with LPS (100 ng/ml) before measuring luciferase activity. The 
activity of luciferase is shown relative to those cells transfected with empty expression vector. 
Expression of TONEBP, TONEBPΔIPT and TONEBPΔRHD protein were examined by 
immunoblotting with anti-Myc antibody. (b) HEK293 cells were transfected with the constructs 
indicated at the top. mRNA expression was examined by RT Q-PCR for NFκB-target genes TNFα, IκBα, 
and IL8, and TonEBP-target genes BGT-1, SMIT, and AR. Data are normalized to those transfected with 
empty vector. Data (mean + s.d., n = 5-6) are representative of three independent experiments. *P < 
0.05 compared to empty. 
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Figure 2-6. Reduced NFκB activity in TonEBPΔ/Δ MEF cells despite normal expression and 
regulation of NFκB 
(a) Schematic representations of TonEBP, TonEBP ΔIPT, TonEBP ΔRHD (see Fig. 3), and protein 
product of the TonEBP Δ allele which lacks exon 6 and 7 leading to an in-frame deletion of a portion of 
RHD-n as indicated. (b) TonEBP+/+ or TonEBPΔ/Δ MEF cells were transfected with the κB-luciferase 
construct. Cells were treated with LPS (100 ng/ml) or vehicle (V) for 6 hours before measuring 
luciferase activity. (c) Cells were treated with LPS for 6 hours. TNFα and IκBα mRNA were quantified 
by RT Q-PCR. (d) Cells were immunoblotted for p65, RelB, c-Rel, p52, p50 and TonEBP. (e) Cells 
grown on coverslips were treated with LPS or vehicle (V), and immunostained for p65 (red) and 
TonEBP (green). Co-localization is shown in orange in merged images. (f) Cells were treated with LPS 
for 0, 5, and 15 min as indicated, and immunoblotted for TonEBP, serine 276 phosphorylated p65 (p-
p65), p65, and hsc70. Data (mean + s.d., n = 4) are representative of two or three independent 
experiments. *P < 0.05 compared to corresponding TonEBP +/+. 
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Figure 2-7. TonEBP knockdown does not affect DNA binding of p65 
(a) RAW264.7 cells were transfected with TonEBP-targeting siRNA (TonE) or scrambled siRNA (Scr) 
followed by treatment with LPS or vehicle (V). Nuclear extracts were prepared and EMSA was 
performed with the N1 probe as in Fig. 2-1b (top). The nuclear extracts were immunblotted for TonEBP 
and p65 (bottom). (b) DAPA was performed with the N1 probe as in Fig. 2-1e. Data are representative 
of two independent experiments.  
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Figure 2-8. The TonEBP Δ protein is unable to recruit p300 co-activator to p65 
(a) TonEBP+/+ or TonEBPΔ/Δ MEF cells were treated with LPS or vehicle (V). Lysates of 
TonEBP+/+ or TonEBPΔ/Δ MEF cells were immunoprecipitated (IP) using anti-p65 antibody 
followed by immunoblotting for p300, TonEBP and p65. (b) Cells were transfected with increasing 
amount of a p300 expression plasmid along with the κB-luciferase reporter. After 6 h treatment with 
LPS, luciferase was measured. A representative of three independent experiments is shown.  
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Figure 2-9. The transactivation domain of TonEBP mediates the NFκB activation 
(a) Schematic representation of the p65-TonEBP fusion constructs. Transactivation domain (TAD) of 
TonEBP (amino acids 618-1476) and its serial deletions were fused to p65 as shown. (b) COS-7 cells 
were transfected with Flag-tagged p65 or various p65-TonEBP fusion constructs along with a κB-
luciferase reporter construct driven. Cells were stimulated for 6 hours with LPS before measuring 
luciferase activity. Expression of the p65-TonEBP fusion proteins was examined by immunoblotting for 
Flag. (c) COS7 cells were transfected with Myc-Yc1 along with a luciferase reporter construct driven 
by κB or TonE. Cells were stimulated for 6 hours with LPS before measuring κB luciferase activity or 
stimulated for 6 hours with hypertonicity before measuring TonE luciferase activity. Data (mean + s.d., 
n = 5-6) are representative of three independent experiments. 
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Figure 2-10. TonEBP-p300 interaction is independent of p65 
(a) MEF cells were transfected with p300-targeted siRNA or scrambled (Scr) siRNA followed by 
stimulation with LPS or vehicle (V). Cell lysates were immunoprecipitated (IP) using anti-p65 antibody 
and immunoblotted for p300, TonEBP and p65. (b) MEF cells transfected with p65-targeted siRNA or 
scrambled (Scr) siRNA were treated as above. Cell lysates were immunoprecipitated using anti-p300 
antibody. (c) MEF cells transfected with TonEBP-targeted siRNA or scrambled (Scr) siRNA were 
treated as above. Cell lysates were immunoprecipitated using anti-p300 antibody. Data are 
representative of two independent experiments.  
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Figure 2-11. TonEBP deficiency breaks down the LPS-induced NFκB enhanceosome assembly 
on TNFα promoter 
RAW264.7 cells were transfected with TonEBP-targeted siRNA or scrambled (Scr) siRNA followed by 
stimulation with LPS or vehicle (V) for 1h. ChIP was performed using normal rabbit IgG, anti-p65 IgG, 
anti-Sp1 IgG, and anti-Pol II IgG. The precipitates were quantified for the N1 region using Q-PCR. A 
representative set of three independent experiments is shown. Data are representative of three 
independent experiments.  
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Figure 2-12. Cerulenin breaks up the TonEBP-p300-p65 interaction and reduces inflammation 
(a) MEF cells were treated without or with cerulenin (10 μM) for 1 h followed by vehicle (V) or LPS 
(100 ng/ml) for an additional 1 h. Cell lysates were immunoprecipitated (IP) using anti-p65 antibody. 
The immunoprecipitates and cell lysates were immunoblotted for p300, TonEBP and p65. (b) PECs 
were treated with 0 to 10 μM cerulenin as indicated for 1 h, followed by LPS for 24 h. Nitrite in the 
medium (open bars) and cell viability based on reduction of MTT (solid bars) were measured. (c) PECs 
transfected with the κB-luciferase construct were treated with vehicle or cerulenin (10 μM) for 1 h, 
followed by vehicle (V) or LPS for an additional 6 h. Luciferase activity was measured from cell lysates. 
(d) PECs were treated as in (c) and mRNA expression for iNOS, COX-2, TNFα, IL-1β, IL-6 and MCP-
1 was measured by RT Q-PCR. (e) PECs pre-treated for 1 h with vehicle or cerulenin (10 μM) were 
stimulated for 24 h with 0, 100, and 1,000 ng/ml of LPS. Expression of iNOS and COX-2 was visualized 
by immunoblotting. Data (mean + s.d., n = 4-5) are representative of three independent experiments. *P 
< 0.05 compared to vehicle. 
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Figure 2-13. Cerulenin reduces inflammation without cytotoxicity 
(a) RAW264.7 cells were treated for 1 h with vehicle, or 1 to 20 μM of cerulenin or BAY11-7082 as 
indicated. The cells were then treated for 24 h with LPS. Nitrite in the media (a) and cell viability (b) 
were measured. Data (mean + s.d., n = 5) are representative of four independent experiments.  
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Figure 2-14. Cerulenin reduces inflammation and septic death in mice 
(a) Mice were intraperitoneally injected with vehicle or cerlenin (60 mg/kg body weight). After 1 h, 
vehicle or GalN/LPS was administered as in Fig. 7. After another hour, TNFα was measured from serum 
samples. Data (mean + s.d., n = 5) are representative of three independent experiments. *P < 0.05 
compared to vehicle. (b) Animals pre-treated with vehicle (blue line) or cerulenin (red line) were 
administered with GalN/LPS as in (a). The animals were monitored for survival. n = 8.  
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Figure 2-15. Cerulenin does not affect nuclear localization, DNA binding, and phosphorylation 
of p65 
(a) RAW264.7 cells were treated for 1 h with vehicle, cerulenin, or BAY 11-7082 (BAY) followed by 
1 h treatment with vehicle (V) or LPS. Nuclear and cytoplasmic fractions were separated and 
immunoblotted for p65, and lamin B. (b) Cells were pretreated with cerulenin and then LPS as above. 
EMSA was performed using nuclear extracts and biotin-labeled N1 probe. Where indicated, anti-p65 
IgG (p65) or control IgG (IgG) was added to supershift p65-DNA complex. In the last lane, 50 times 
concentration of unlabeled (cold) N1 was added for competition. Bottom panel shows p65 
immunoblot of the nuclear extracts. (c) Vehicle (-) or cerulenin treated cells were incubated with LPS 
for 0 to 30 min as indicated, and immunoblotted for serine 276 phosphorylated p65 (p-p65) and p65. 
Data are representative of three independent experiments. 
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Figure 2-16. IL-4 diminishes the expression of TonEBP which reduces the expression of M2 genes 
in macrophages 
(a) RAW264.7 cells were treated for 24 h with vehicle (Con), LPS (100 ng/ml), or IL-4 (10 ng/ml) and 
immunoblotted for TonEBP and Hsc70. (b) Cells were treated with LPS or IL-4 up to 12 h as indicated. 
Quantitative RT-PCR was performed for TonEBP mRNA and expressed in fold over 0h. s.d. bars are 
smaller than the circles (n = 3). *P < 0.05 compared to 0 h. (c) Cells transfected with scrambled (Scr) 
or TonEBP targeted siRNA were treated for 6 h with vehicle (Con), LPS, or IL-4. Quantitative RT-PCR 
was performed for mRNA for IL-10, Arg-1 and CD206, and expressed in fold over Scr siRNA and Con. 
(d) Cells infected with adenovirus expressing TonEBP (Ad-TonEBP) or with empty vector (Ad-EV) 
were treated with LPS or IL-4. Data (mean + s.d., n = 3) are representative of three independent 
experiments. *P < 0.05 compared to corresponding scrambled siRNA or Ad-EV. 
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Figure 2-17. TonEBP deficiency enhances the expression and signaling of IL-10 in M1 
macrophages 
(a–d) RAW264.7 cells transfected with scrambled (Scr) or TonEBP-targeted siRNA and treated with 
LPS (100 ng/ml) for up to 24 h as indicated (a,b), 18 h (c) or 6 h (d). IL-10 concentration in the medium 
was measured by ELISA (a) and IL-10 mRNA abundance by quantitative RT-PCR (b). In (c), 
immunoblotting was performed for SOCS3, STAT3, phospho-STAT (p-STAT3), and Hsc70. In (d), 
mRNA for IL-4Rα , SOCS3 and Bcl-3 was measured. (e,f) Thioglycollate-elicited peritoneal 
macrophages (PM) or bone marrow-derived macrophages (BMDM) obtained from TonEBP +/Δ mice 
and their TonEBP +/+ littermates were treated with vehicle (Con) or LPS (100 ng/ml) for 18 h (e) or 6 
h (f). Immunoblotting for TonEBP and Hsc70 (e) and quantitative RT-PCR for IL-10 mRNA (f) were 
performed. Data (mean + s.d., n = 3) are representative of three independent experiments. 
*P < 0.05 compared to corresponding scrambled siRNA or TonEBP +/Δ mice. 
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Figure 2-18. TONEBP deficiency enhances the expression of IL-10 in primary human 
macrophages obtained from 3 donors 
The human macrophages were transfected with scrambled (Scr) or TONEBP-targeted siRNA. 48 h later, 
the cells were treated with vehicle (Con) or LPS (100 ng/ml) for 6 h (a,d), 1 and 3 h (b), or 6 h (c). 
Immunoblotting was performed for TONEBP and HSC70 (a). In (b), IL-10 mRNA abundance was 
measured by quantitative RT-PCR. In (c), IL-10 concentration in the medium was measured by ELISA. 
In (d), mRNA for ARG-1, CD206, SOCS3, and BCL-3 was measured. Mean + s.d., n = 3. *P < 0.05 
compared to corresponding scrambled siRNA. 
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Figure 2-19. β-lapachone reduces TonEBP expression and enhances IL-10 expression 
RAW264.7 cells were treated for 1 h with vehicle (Veh) or 10 μ M β -lapachone (β -LAP), followed by 
a 6 h treatment with vehicle (Con), 100 ng/ml LPS, or additional 75 mM NaCl. (a) Immunoblotting was 
performed for TonEBP and Hsc70. (b,c) From the LPS and NaCl treated cells, mRNA for the genes 
indicated was measured by quantitative RT-PCR. mRNA abundance in β -LAP over that of Veh is shown. 
Data (mean + s.d.; n = 3 to 5) are representative of three independent experiments. *P < 0.05 compared 
to vehicle. 
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Figure 2-20. TonEBP deficiency increases PPARγ1 expression in RAW264.7 cells 
(a) Scr siRNA or TonEBP siRNA transfected RAW264.7 cells were treated for 24 h with vehicle (Con), 
LPS (100 ng/ml), or IL-4 (10 ng/ml) and immunoblotted for PPARγ, pSTAT6, STAT6, C/EBPβ, 
TonEBP and Hsc70. (b) Scr siRNA or TonEBP siRNA transfected cells were treated with IL-4 for 12 h. 
Quantitative RT-PCR was performed for PPARγ1 and CD36 mRNA and expressed in fold over 0h, Scr 
siRNA. Data (mean + s.d., n = 3) are representative of four independent experiments. *P < 0.05 
compared to scrambled siRNA. 
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Figure 2-21. Myeloid specific TonEBP deficiency improves metabolic profiles in obesity 
(a) Body weights and (b) fasting blood glucose level (c) GTT and ITT (d) serum insulin (e) serum AST 
and ALT concentration of male WT (TonEBP fl/fl) and myeloid specific TonEBP deficient mice (TonEBP 
fl/fl, LysM cre) on a C57BL/6 background, fed either a NC or a HFD (n = 7–10 mice per group). Data 
(mean + s.e.m.) are representative of four independent experiments. *P < 0.05 compared to WT 
(TonEBP fl/fl).  
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Figure 2-22. Myeloid specific TonEBP deficiency reduces adipose tissue inflammation by 
regulating macrophage polarization 
(a) Representative images of H&E stained sections of from WT (TonEBP fl/fl) and myeloid specific 
TonEBP deficient mice (TonEBP fl/fl, LysM Cre) fed with HFD. (b) pro-inflammatory gene (TNFα, IL1b, 
MCP1 and F4/80) and (c) anti-inflammatory and M2 genes (IL10, Ym1, Mgl1, CD206 and PPARγ1) 
mRNA levels in eWAT from WT (TonEBP fl/fl) and myeloid specific TonEBP deficient mice (TonEBP 
fl/fl, LysM Cre) fed with HFD (n = 7–10). (d) pro-inflammatory gene (TNFα and F4/80) mRNA levels 
in liver. (e) Representative FACS analysis plots and (f) average percentages for M1 (F4/80+ CD11b+ 
CD11C+ CD206-) and M2 (F4/80+ CD11b+ CD11C- CD206+) macrophage population in eWAT from 
WT (TonEBP fl/fl) and myeloid specific TonEBP deficient mice (TonEBP fl/fl, LysM Cre) fed with HFD 
(n = 5). (g) Human leukocyte TONEBP mRNA in blood from non-diabetic and diabetic human (n=12 
total individuals). Data (mean + s.e.m., n = 7-10) are representative of three independent experiments. 
*P < 0.05 compared to TonEBP fl/fl. 
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Figure 2-23. Schematic model for the role of TonEBP in obesity-induced insulin resistance 
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Chapter3. Adipocyte TonEBP promotes obesity through the suppression of 
WAT beiging 
 
3-1. Introduction 
 
The single most important variable in the pathogenesis of metabolic disease is energy balance. If 
energy consumption exceeds energy expenditure, weight gain and ultimately obesity result. Excess 
energy is stored as lipids in adipose tissue, but the unfettered expansion of adipose tissue can result in 
a pathological condition characterized by hypoxia and leading to insulin resistance, impaired 
thermogenic activity, and chronic inflammation [1-2]. Adipose tissue is also capable of transforming 
chemical energy into heat, thus inhibiting excessive fat accumulation, through the activity of specialized 
thermogenic adipocytes. In addition to the classical brown adipocytes that largely comprise brown 
adipose tissue, and which constitutively express thermogenic genes, ‘brown-like’ adipocytes, known as 
beige cells, are also present in white adipose tissue, and thermogenesis can be induced in these cells in 
response to a variety of activators [3]. Activation of the thermogenic gene program in brown or beige 
adipocytes increases systemic energy expenditure and can ameliorate or prevent the development of 
obesity-associated metabolic disorders as a result. Thus, efforts aimed at gaining a deeper understanding 
of the regulation of energy storage, mobilization, and use by adipocytes may lead to the identification 
of potential future therapies for metabolic disease [4]. 
TonEBP, also known as nuclear factor of activated T cells 5 (NFAT5), belongs to the Rel family of 
transcriptional factors including nuclear factor κB (NFκB) and NFAT1-4 [15, 6]. TonEBP has a variety 
of molecular and physiological functions. TonEBP was initially identified as the central DNA binding 
transcription factor of cellular response to hypertonic stress by regulating genes such as BGT1, SMIT, 
AR and HSP70 [5, 7-9]. Recent studies have revealed that TonEBP act as a transcriptional co-activator 
in activation of NFĸB and it promotes the M1 activation of macrophages and pro-inflammatory 
responses [10]. Consequently, TonEBP haplo-deficiency is associated with reduced inflammation 
leading to prevention of inflammatory and autoimmune diseases including rheumatoid arthritis [11], 
atherosclerosis [12] and encephalomyelitis [13] in mouse models. The more recent study showed that 
TonEBP inhibits adipogenesis through the suppression of PPARγ2 expression, suggesting that TonEBP 
is one of the key transcription factors that control adipogenesis [29]. In this regulation, TonEBP is a 
transcriptional co-suppressor in PPARγ2 transcription by recruiting histone methyltransferase to the 
promoter. These studies demonstrated that TonEBP has pleiotropic functions including DNA binding 
transcription factor, transcriptional co-activator and transcriptional co-repressor in inflammation and 
adipocyte differentiation. Inflammation and adipocyte differentiation is critical for obesity and type 2 
diabetes development. However, the role of TonEBP in obesity was uncovered.  
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Here, we report that the expression of TonEBP in adipose tissues is required for the development of 
obesity and insulin resistance in mice, whereas its ablation enhances adipocyte thermogenesis and 
beiging, and prevents ectopic deposition of triglyceride. The substantial expression of TonEBP in the 
adipose tissue of obese mice and its significant association with indices of metabolic dysfunction 
suggest that TonEBP represents a novel target for the treatment of obesity, type 2 diabetes, and its 
complications. 
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3-2. Materials and methods 
 
Animals  
All the methods involving live mice were carried out in accordance with the approved guidelines. 
All experimental protocols were approved by Institutional Animal Care and Use Committee of the 
Ulsan National Institute of Science and Technology (UNISTACUC-12-15-A).  
TonEBP haplo-deficient mice (TonEBP+/Δ) were described previously [5]. 
Mice carrying the loxP-targeted TonEBP gene (TonEBPfl/fl) were reported previously. Transgenic 
mice expressing Cre recombinase under the control of Adiponectin (AQ) promoter were purchased 
from The Jackson Laboratory (Bar Harbor, ME, USA). TonEBPfl/fl and LysMcre or AQcre mice 
crossed to yield mice with specific targeted deletion of TonEBP in macrophages or adipocytes 
(TonEBPfl/fl, LysMcre, TonEBP fl/fl, AQcre). 
For obese mice model, mice at 8 weeks age were fed with high fat diet (60% fat by kcal) or normal-
chow diet (10% fat by kcal) during 16 weeks. Mice were intraperitoneally injected with RG108 
(Cayman, 12 mg/kg every 2 days) before feeding with high fat diet. 
 
Cells and reagents 
Pre-adipocyte cell line 3T3-L1 cells and macrophage cell line RAW264.7 cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS; Thermo 
fisher scientific Inc, Waltham, MA, USA) and penicillin/streptomycin (100U/ml and 100μg/ml; GE 
healthcare life sciences, Logan, UT, USA). For induction of adipocyte differentiation, adipogenesis 
inducing medium (AIM) including 1μM dexamethasone, 0.5 mM isobutylmethylxanthine, and 1μM 
insulin, 125 μM indomethacin and 1 nM Triiodothyronine (T3) was used as described [14]. Cells were 
maintained at 37°C in incubator with 5% CO2. Cells were treated with isoproterenol (Sigma Aldrich, 
USA) for 4h after adipocyte differentiation. Anti-Adrb3 (Abcam, Cambridge, UK), anti-Hsc70 
(Rockland, Gilbertsville, PA, USA) and anti-TonEBP antibody [5] were used for immunoblotting. 
 
Human adipocytes samples 
Adipocyte RNA of subcutaneous abdominal adipose tissue from 15 Saudi Arabian subjects were 
obtained from the Obesity Research Center at the College of Medicine of King Saud University, 
Riyadh, Saudi Arabia. The experiments were approved by the College of Medicine Ethics Committee, 
King Saud University. Total RNA was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer's instructions. cDNA was synthesized by M-MLV reverse 
transcriptase (Promega, Madison, WI, USA). After reverse transcription, real time PCR was 
performed using SYBR Green I Master and LightCycler 480 II (Roche, Rotkreuz, Switzerland). 
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Measured cycle threshold (Ct) values were normalized with 36B4 and they were expressed as fold-
over control samples. 
 
Transfection 
When the cells grow at the 70% of confluence, cells were transfected for 48 h with TonEBP siRNA 
or control scrambled siRNA (10nM) and miR-negative control, miR-30b or miR-30c (100nM) using 
lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) following the manufacturer’s instructions. 
 
Isolation and differentiation of preadipocytes 
Preadipocytes were isolated from inguinal white adipose tissue obtained from 4-weeks-old animals. 
Inguinal white adipose tissue were minced in DMEM/F12 medium and digested with 10 ml HEPES 
buffer containing 1mg/ml type II collagenase. They were incubated at 37˚C with gentle shaking for 1 
hr. After incubation, 10 ml of DMEM/F12 were added and they were centrifuged at 500g for 15 min. 
Stromal vascular cells (SVCs) were incubated with 5ml of RBC lysis buffer (Sigma) for 5 min at 
room temperature and then they were filtered with a 40μm filter after addition of 10ml of 
DMEM/F12. After centrifugation at 500g for 5 min, SVCs were differentiated to adipocyte with AIM. 
 
Immunoblot assay 
Cell were washed two times with cold PBS and lysed in RIPA buffer (0.01M Tris, pH7.4, 0.15M 
NaCl, 0.001M EDTA, 0.001M EGTA, 1% Triton X-100, 0.002M PMSF and protease inhibitor 
(roche)). After centrifugation of lysate, supernatant was used for immunoblot assay. Protein 
concentration was measured by BCA protein assay system (Pierce, Rockford, IL, USA). Equal 
amounts of protein from each sample were separated by SDS-PAGE and immunoblotted using 
specific primary antibodies. HRP-conjugated mouse, rabbit and goat secondary antibodies were used 
for detection. The antigen-antibody binding was detected by enhanced chemiluminescence Western 
blotting detection reagents (GE healthcare life sciences).  
 
RNA isolation and real-time PCR 
Total RNA was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer's instructions. cDNA was synthesized by M-MLV reverse transcriptase (Promega, 
Madison, WI, USA). After reverse transcription, real time PCR was performed using SYBR Green I 
Master and LightCycler 480 II (Roche, Rotkreuz, Switzerland). Measured cycle threshold (Ct) values 
were normalized with cyclophilin A or 36B4 and they were expressed as fold-over control samples. 
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Metabolic analysis 
Fasting blood glucose, body weight and food intake were measured weekly, and body composition 
was measured using a quantitative nuclear magnetic resonance system (EchoMRI100V; Echo Medical 
Systems, Houston, TX, USA). Oxygen consumption, carbon dioxide production, heat production and 
locomotor activity were monitored using Comprehensive Lab Animal Monitoring System (CLAMS; 
Columbus Instruments, Columbus, OH, USA). Mice were given an orally injection of D-glucose (2 
g/kg body weight) after overnight starvation for the glucose tolerance test (GTT) and were intra- 
peritoneally injected with insulin (0.75U/kg body weight) for insulin tolerance test (ITT). Serum 
glucose levels were determined in tail blood samples using a glucometer. Body temperatures were 
measured using a digital thermometer (TD-300; Shibaura Electronics, Tokyo, Japan) 
 
Nuclear and cytoplasmic fractionation 
Cells were harvested by using scrapper and centrifugation at 500 g. The cell pellet was washed by 
suspension with PBS. The cell nucleus and cytoplasm were separated by using Nuclear and 
Cytoplasmic extraction kit (Pierce) according to manufacturer’s instruction. Nuclear fraction was 
confirmed by Lamin B. 
 
Electromobility shift assay 
EMSA assay were performed using Lightshift Chemiluminescent EMSA kit (Pierce). 5 μg of 
nuclear extracts were incubated with poly(dI:dC), binding buffer and 5’ biotinylated DNA (5’- 
CAATTTGGAAAAATTTTGACT -3’ for TonEBP binding site on Adrb3 promoter) at room 
temperature for 20 min. Samples were separated by electrophoresis for 4 h in 4% (40% 29:1 
acrylamide/bis solution) gel for TonEBP. The detection was performed according to manufacturer’s 
instructions. 
 
Immunoprecipitation assay 
  Cell lysates (10-500μg) were prepared using RIPA buffer in a tube on ice. Antibody (1-5μg) was 
added to cell lysate and they were incubated for overnight at 4°C under rotary agitation. 40μl of 
protein A/G agarose beads (GE healthcare) was added and incubated for 2 hr at 4°C under rotary 
agitation. The bead-antibody-antigen complex was spin downed by centrifugation at 4°C for 1min and 
removed supernatant. The complex was washed for 10 min by RIPA buffer at 4°C and it was repeated 
with three times. After wash, 40μl of sample buffer was added and boiled at 95°C for 5min and 
centrifugated with top speed for 1min at room temperature. The samples were transferred to new tube 
and analyzed by immunoblotting.  
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Chromatin immunoprecipitation assay 
Cells were grown in 10 cm diameter culture dishes and with LPS when indicated. Fixation was 
performed with 1% formaldehyde at room temperature for 10 min. The fixation was stopped with 
0.125 M glycine for 5 min at room temperature. After three washes with cold PBS, cells were 
collected and lysed in 1 ml of SDS lysis buffer (1% SDS, 10 mM EDTA and 50 mM Tris-HCl pH 8.1) 
for 10 min on ice. Cell lysates were sonicated (Bioruptor KRB-01, BMS, Tokyo, Japan) for six cycles 
of 20 s on plus 30 s off with constant frequency and maximum intensity to obtain DNA fragments 
between 400 and 1,000 bp. Each sample was diluted 10× in dilution buffer (0.01% SDS, 1.1 % Triton 
X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1 and 167 mM NaCl) for immunoprecipitation. 
Samples were pre-cleared with protein A Sepharose beads (Millipore, Bedford, MA, USA) that were 
previously pre-adsorbed with salmon sperm DNA for 1 h at 4°C. Specific antibodies were added after 
removing the pre-clearing beads: anti-PolII IgG (Pierce), and normal rabbit IgG (Abcam, Cambridge, 
UK), anit-TonEBP serum, and normal rabbit serum (Merck millipore, Darmstadt, Germany). After 
adding antibodies, the lysates were incubated overnight at 4°C. Protein A Sepharose beads were then 
added, incubated for 2 h at 4°C, and then washed with low salt washing buffer (0.1% SDS, 1% Triton 
X-100, 20 mM Tris-HCl pH 8.1, 2 mM EDTA, and 10 mM NaCl), high salt washing buffer (0.1% 
SDS, 1% Triton X-100, 20 mM Tris-HCl pH 8.1, 2 mM EDTA and 500 mM NaCl), LiCl washing 
buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholic acid, 1 mM EDTA and 10 mM Tris-HCl pH 8.1) and 
twice with final washing buffer (10 mM Tris-HCl pH 8.0 and 1 mM EDTA). To elute the DNA, beads 
were incubated with elution buffer (1% SDS and 100 mM NaHCO3) for 20 min at 65 °C. To reverse 
the cross-linking, samples were incubated overnight at 65°C 200 mM NaCl, 30 min at 37°C with 50 
μg/ml RNase (Pierce) and 2 hr at 45°C with 100 μg/ml proteinase K. DNA was purified using the 
QIAGEN PCR purification system. DNA was then subjected to RT-qPCR using primers; 5’- 
GACAACTCATGGAGCAGTCTT -3’ and 5’- CTTACTTACTGTGCCATCTCCC -3’ for Adrb3 
promoter. Immunoprecipitated DNA from each sample was normalized to its respective chromatin 
input. 
 
Luciferase assay 
Cells were transfected with either a TonE-driven Photinus luciferase plasmid or an adrb3 promoter 
6kb-driven luciferase plasmid in pGL4.74 (hRluc/TK, Promega). The Renilla luciferase reporter 
plasmid (pRL-TK, Promega) was used as a control for transfection efficiency. Luciferase activity was 
measured using the Dual-Luciferase Assay System (Promega) according to the manufacturer’s 
instructions. Luciferase activity was normalized by activity of renilla luciferase. 
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ELISA 
Leptin and adiponectin in serum from mice were analyzed by ELISA using a commercial kit (R&D 
Systems). Insulin was analyzed by ELISA using a commercial kit (Alpco, Salem, NH, USA). 
 
Lipid analysis  
Triacylglycerol (TG), free fatty acid (FFA) and cholesterol level in serum was measured using TG, 
FFA or cholesterol quantification kit (Abcam) according to manufacturer’s instructions. 
 
MNase accessibility assay by qPCR  
MNase accessibility assay by q-PCR was performed using micrococcal nuclease (MNase) 
described as previously with minor modification50. Washed cells were lysed in cold NP-40 lysis 
buffer (10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 0.15mM spermine 
(Sigma), 0.5 mM spermidine(Sigma)), followed by incubation on ice for 5 min. Nuclei were pelleted 
by centrifuge at 5000 rpm for 3 min at 4˚C and resuspended with MNase digestion buffer without 
CaCl2 (10 mM Tris-HCl (pH 7.4), 15 mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 mM 
spermidine). After centrifugation, the nuclei were resuspended with MNase digestion buffer 
supplemented with CaCl2. Then, half of the each sample was treated MNase with 5 unit/sample and 
the other half of that was treated digestion buffer, and samples were incubated at 37˚C for 1 min. The 
digestion reaction was stopped by addition of stop solution (100mM EDTA/10mM EGTA (pH 8.1) in 
10 mM Tris-HCl (pH 7.4)). RNaseA (10μg/sample) and proteinase K (100μg/sample) were added and 
samples were incubated at 37˚C overnight. DNA, purified by Phenol/chloroform/isoamyl alcohol 
extraction, was analyzed by q-PCR using primer pairs covering near -1.8kb region of the Adrb3 
promoter. Chromatin accessibility was calculated from (amount of PCR product in undigested sample) 
/ (amount of PCR product in digested sample).  
 
DNA methylation analysis using bisulfite sequencing 
 DNA was purified by DNA purification kit (Qiagen). Bisulfite conversion was performed using 
EpiTect Bisulfite Kit (Qiagen). After conversion, Adrb3 promoter region was amplified by PCR using 
primers designed by Methprimer software (www.urogene.org/methprimer/index1.html). Amplified 
DNA was cloned into bacteria by TOPO TA cloning kit (Invitrogen). Plasmid from each clone was 
sequenced by Macrogen commercial services. 
 
Statistical analysis  
Data are presented as means + s.d. or + s.e.m. Statistical significance (p < 0.05) was estimated by 
student’s t-test. All statistics was performed with GraphPad Prism 5.0 software (GraphPad, San Diego, 
CA, USA). 
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3-3. Results 
 
3-3-1. Adipose TonEBP expression increases in obesity 
It was previously reported that TonEBP is expressed in many tissues. However, we found that 
TonEBP expression in inguinal white adipose tissue (iWAT) is very low in lean mice (Fig. 3-1). 
Interestingly, TonEBP mRNA and protein expression was significantly upregulated in iWAT and 
epididymal white adipose tissue (eWAT) of male mice fed a high fat diet (HFD; 60% energy as fat) for 
16 weeks, compared with control mice fed a normal chow diet (NC; 10% energy as fat) (Fig. 3-2a and 
b). Similarly, TonEBP mRNA expression was higher in iWAT from 16-week-old leptin receptor 
mutant db/db (Leprdb/db) obese mice (Fig. 3-2c). In addition, HFD-fed mice exhibited lower mRNA 
expression of the thermogenic genes PPARGC1A (encoding PPARγ coactivator 1α (PGC1-α)), Dio2, 
CPT1α, Cidea, PPARα, and Adrb3, and of markers of beiging (UCP-1, CD137, and TMEM26), in 
iWAT (Fig. 3-2d and e). Subcutaneous adipose TONEBP mRNA expression also correlated with the 
body mass index (BMI) of a group of subjects from Saudi Arabia (Fig. 3-2f). Together, these data 
suggest that adipose TonEBP expression is associated with obesity-induced metabolic dysfunction, 
including impaired thermogenic function. 
 
3-3-2. TonEBP haplo-deficient mice are resistant to the development of diet-induced obesity 
To study the physiological role of TonEBP, TonEBP haplo-deficient mice and wild-type (WT) 
littermates were fed either a NC or HFD for up to 15 weeks, starting at 8 weeks of age. The 
homozygous TonEBP-deficient mice died soon after birth. The haplo-deficient mice on the NC 
showed a similar weight gain to WT mice (Fig. 3-3a) but those on the HFD were resistant to weight 
gain (Fig. 3-3a and b). Food intake was similar between the groups (Fig. 3-3c). To further assess the 
body composition changes accompanying this decrease in body mass, a whole body echo MRI 
analysis was performed. The lower body mass of TonEBP haplo-deficient mice after 8 weeks on a 
HFD was accounted for a reduction in fat mass, without an alteration in body length or lean body 
mass (Fig. 3-3d). Accordingly, the haplo-deficient mice exhibited lower masses of inguinal, 
epididymal, and dorsal fat pads (Fig. 3-3e), indicating resistance to diet-induced obesity. We also 
observed that TonEBP haplo-deficient mice on a Leprdb/db background were relatively protected 
against weight gain and adiposity compared with WT mice (Fig. 3-4a and b). 
 
3-3-3. Adipocyte TonEBP suppresses thermogenesis and beiging of WAT 
A reduction of adipose tissue weight without an alteration in food intake (Fig. 3-3e) suggested a 
potential increased energy expenditure by TonEBP haplo-deficient mice. The measurement of oxygen 
consumption (VO2) and carbon dioxide production (VCO2) over 72 h (including both light and dark 
phases) showed higher consumption rates in the haplo-deficient mice (Fig. 3-5a and b). Consistent 
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with the higher VO2, the haplo-deficient mice generated more heat (Fig. 3-5c) and had a ~0.6°C 
higher body temperature (Fig. 3-5d). In addition, their body temperature remained higher even in a 
cold environment (4°C) for up to 6 h (Fig. 3-5e), suggesting enhanced adaptive thermogenesis and 
energy expenditure. 
Reduced thermogenesis is a characteristic feature of obesity in humans and mice [20]. We 
examined whether TonEBP affects adipose thermogenic and beige marker gene expression. As 
expected, we found an upregulation of thermogenic genes, such as PGC1-α, Dio2, and Cidea (Fig. 3-
6a), and beige marker genes, such as uncoupling protein-1 (UCP-1), CD137, and TMEM26, in iWAT 
(Fig. 3-6b) from TonEBP haplo-deficient mice. Furthermore, assay of iWAT from haplo-deficient 
mice exposed to a cold environment revealed a significant upregulated the expression of these genes, 
and of UCP-1 protein (Fig. 3-6c), consistent with the observations made under ambient conditions. 
Histological and immunohistochemical analysis of iWAT revealed features of beiging WAT, including 
multilocular lipid droplets and higher expression of UCP-1 by adipocytes (Fig. 3-6d). 
Consistent with the in vivo data, enhanced basal and β3 adrenergic agonist (isoproterenol)-
stimulated expression of thermogenic genes and hormone-sensitive lipase (HSL) was observed in 
TonEBP haplo-deficient primary adipocytes differentiated from the stromal vascular fraction and in 
3T3-L1 cells transfected with small interfering RNA (siRNA) targeting TonEBP (Fig. 3-6e and 3-7a). 
In addition, after adipocyte differentiation, adenovirus-mediated overexpression of TonEBP reduced 
basal and isoproterenol-stimulated expression of these genes (Fig. 3-7b). These findings indicate that 
TonEBP deficiency promotes energy expenditure through the activation of thermogenesis and beiging 
of WAT in adipocytes. 
 
3-3-4. TonEBP haplo-deficient mice resist obesity-induced insulin resistance and metabolic 
dysfunction 
We next assessed glucose homeostasis and insulin sensitivity in HFD-fed WT and haplo-deficient 
mice. TonEBP haplo-deficient mice maintained lower fasting glucose levels than WT mice between 
weeks 1 and 15 of HFD feeding (Fig. 3-8a) and showed improved glucose tolerance and insulin 
sensitivity in glucose (GTT) and insulin (ITT) tolerance tests (Fig. 3-8b). After 15 weeks of HFD 
feeding, the haplo-deficient mice showed lower serum fasting glucose and insulin concentrations than 
WT controls (Fig. 3-8c). Furthermore, TonEBP haplo-deficient Leprdb/db obese mice had lower blood 
glucose levels than WT mice (Fig. 3-8d). To confirm the effect of TonEBP deficiency on insulin 
sensitivity, we injected HFD-fed mice with insulin and found that Akt activation was significantly 
enhanced in the eWAT and liver of haplo-deficient mice (Fig. 3-8e). 
In addition to its role in lipid storage, adipose tissue also functions as an endocrine organ, secreting 
a large number of polypeptide hormones, termed adipokines, which can modify systemic glucose 
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homeostasis and insulin sensitivity. We measured serum adipokine levels in the haplo-deficient mice 
and showed that levels of the anti-diabetic adipokine adiponectin [15] were significantly higher in 
haplo-deficient mice on the HFD (Fig. 3-9a, left). Consistent with this, adiponectin mRNA expression 
was higher in HFD-fed haplo-deficient mice than in WT mice (Fig. 3-9a, right). Levels of serum 
leptin, a pro-diabetic adipokine, are positively correlated with increasing adiposity [16]. Serum leptin 
level remained low in the HFD-fed haplo-deficient mice (Fig. 3-9b, left), while leptin mRNA levels 
were lower in HFD haplo-deficient mice than in WT mice (Fig. 3-9b, right). These data indicate that 
TonEBP deficiency led to an adipokine profile favoring maintenance of insulin sensitivity. 
Histological analysis revealed significantly lower lipid accumulation in brown adipose tissue and 
smaller adipocyte size in iWAT from HFD-fed haplo-deficient mice (Fig. 3-9c), indicating that 
TonEBP deficiency leads to healthier adipocyte morphology as a result of lower triglyceride 
accumulation, possibly due to an increased rate of lipolysis. In addition, eWAT contained significantly 
fewer crown-like structures, lower macrophage infiltration, and lower expression of the inflammatory 
cytokine tumor necrosis factor α (TNFα) in HFD-fed haplo-deficient mice (Fig. 3-9d and e). In eWAT, 
obesity-induced inflammatory responses resulted in adipocyte dysfunction, characterized by lower 
expression of genes involved in lipid metabolism (Fig. 3-9f), but expression of these genes was 
restored in TonEBP haplo-deficient mice (Fig. 3-9g). 
Chronic exposure of mice to a HFD causes fatty liver (steatosis) and increased liver mass [19]. 
Both C57/BL6 and Leprdb/db mice haplo-deficient for TonEBP had lower liver mass than WT mice 
(Fig 3-10a and 3-10b). TonEBP haplo-deficient mice also had smaller lipid droplets in their 
hepatocytes and a lower serum alanine aminotransferase (ALT) concentration than WT mice (Fig. 3-
10c and d). 
HFD-fed haplo-deficient mice did not show high fasting serum cholesterol (total and low density 
lipoprotein (LDL)) levels, and these were thus lower than those of WT mice (Fig. 3-11). Consistent 
with increased expression of the key lipolytic enzyme, HSL, in haplo-deficient mice (discussed 
below), serum triglyceride concentration was lower, but there was no difference from controls in 
serum free fatty acid (FFA) concentration (Fig. 3-11). 
These data suggest that TonEBP is a critical factor that mediates the detrimental effects of HFD-
induced obesity, such as altered serum adipokine secretion, deleterious plasma lipid profile, hepatic 
steatosis and insulin resistance. 
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3-3-5. TonEBP suppresses Adrb3 gene expression in isolated adipocytes 
Stimulation of β3-adrenergic receptor (Adrb3) signaling increases thermogenesis and HSL-
mediated lipolysis, leading to reduced fat mass [21]. Interestingly, we found that the HFD-mediated 
reduction in expression of Adrb3 is restored in the iWAT of TonEBP haplo-deficient mice (Fig. 3-
12a). Furthermore, there was a trend towards higher expression of Adrb3 in the iWAT of haplo-
deficient mice exposed to a cold environment (Fig. 3-12b). Consistent with the in vivo study, Adrb3 
expression was increased in primary adipocytes isolated from the haplo-deficient mice (Fig. 3-12c). 
Its expression was also higher in both basal and isoproterenol-stimulated TonEBP-silenced 3T3-L1 
cells (Fig. 3-12d) and lower in 3T3-L1 cells overexpressing TonEBP (Fig. 3-12e). These data 
demonstrate that TonEBP downregulates Adrb3 expression in adipocytes. 
We next investigated the molecular basis of this TonEBP-mediated Adrb3 gene suppression. First, 
we constructed a pGL3 luciferase reporter vector by inserting a 5.9 kb promoter sequence from the 
mouse Adrb3 gene (Fig. 3-13a). TonEBP knockdown stimulated Adrb3 promoter-driven luciferase 
expression in 3T3-L1 adipocytes (Fig. 3-13b). Next, because the mouse Adrb3 promoter contains one 
putative TonEBP consensus binding sequence (Fig. 3-13a), we investigated whether TonEBP bound to 
this putative binding site in 3T3-L1 cells using an electrophoretic mobility shift assay, and found that 
it did (Fig. 3-13c). To confirm this interaction, we performed chromatin immunoprecipitation in WT 
and TonEBP-silenced 3T3-L1 cells. Fragments of the Adrb3 promoter containing the TonEBP binding 
sites were precipitated using a TonEBP antibody, and this was reduced by TonEBP knockdown (Fig. 
3-13d). 
Next, we evaluated the chromatin accessibility in the promoter region by analyzing sensitivity to 
micrococcal nuclease. Chromatin accessibility was enhanced by TonEBP knockdown at both the 
TonEBP binding region (region A in the Adrb3 promoter) and the transcription start site (TSS) region 
(the B and C region of the Adrb3 promoter) (Fig. 3-14a). 
We further confirmed TonEBP-mediated transcriptional inhibition at the Adrb3 promoter by 
showing higher RNA polymerase II binding at the Adrb3 promoter in TonEBP knockdown adipocytes 
(Fig. 3-14b). A recent study reported that DNA methylation is associated with insulin resistance and 
thermogenic gene regulation. TonEBP deficiency in iWAT and 3T3-L1 reduced DNA methylation in 
the B and C region of the Adrb3 promoter, demonstrated using bisulfite sequencing (Fig. 3-14c and 
d). Among the DNA methyltransferases, we found that DNA methyltransferase 1 (DNMT1) was 
recruited to the Adrb3 promoter through its interaction with TonEBP (Fig. 3-15a and b). Taken 
together, these findings suggest that TonEBP is recruited to the Adrb3 promoter as a transcriptional 
repressor. 
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3-3-6. DNMT inhibition enhances Adrb3 expression and beiging of WAT 
To elucidate the potential role of DNA methylation in WAT beiging, we used RG108, which is a 
DNMT inhibitor. When mice were intraperitoneally injected with RG108 (12 mg/kg every 2 days), 
they resisted HFD-induced gains in body mass (Fig. 3-16a and b), fat mass (Fig. 3-16b and c), and 
fasting glucose (Fig. 3-16d). Consistent with the in vitro data, RG108-injected mice demonstrated 
higher energy expenditure (Fig. 3-17a-c), resistance to the cold (Fig. 3-17d), and enhanced beiging of 
WAT (Fig. 3-71e and f). Treatment of adipocytes with RG108 enhanced UCP-1 and Adrb3 expression 
in a dose-dependent manner, without affecting expression of TonEBP (Fig. 3-17g). Since RG108 
inhibits all of the DNMTs, we examined whether DNMT1 specifically regulated the expression of 
UCP-1 and Adrb3 and Adrb3 promoter activity by silencing DNMT1 expression using siRNA in 
adipocytes. The protein and mRNA expression of UCP-1 and Adrb3, and Adrb3 promoter activity, 
were reduced by DNMT1 knockdown (Fig. 3-18a and b). These data show that DNMT1-induced 
DNA methylation suppresses the beiging of WAT and its effects on energy expenditure. 
 
3-3-7. miR-30 promotes thermogenesis in adipocytes by targeting TonEBP 
miRs inhibit translation or induce target mRNA degradation by base-pairing to recognition sites 
[24, 25]. The microRNA-30 (miR-30) family are potent regulators of thermogenesis in adipocytes 
[22], and miR-30 is downregulated in obese mice [23]. Using prediction program in TargetScan 
Mouse 6.2 (www.targetscan.org), we found that TonEBP is a potential target gene for miR-30, 
possessing two binding sites for miR-30b and miR-30c in its 3’ UTR (Fig. 3-19a). TonEBP mRNA 
and protein expression was significantly reduced in 3T3-L1 adipocytes transfected with miR-30b and 
miR-30c mimics (Fig. 3-19b). Consistent with this, miR-30b and miR-30c mimic administration 
enhanced mRNA expression of thermogenic genes (Fig. 3-19c). These data suggest that miR-30b and 
miR-30c would suppress TonEBP expression in lean mice, while in obese mice TonEBP expression 
would increase as a result of the lower levels of miR-30b and miR-30c, resulting in lower expression 
of thermogenic genes. 
 
3-3-8. Adipocyte-specific TonEBP knockout mice have a similar phenotype to TonEBP haplo-
deficient mice 
To further investigate the specific role of adipocyte TonEBP in thermogenesis and in the 
development of obesity in response to HFD feeding, we generated adipocyte-specific knockout mice 
(AKO) using the Cre-lox system (TonEBP fl/fl; adiponectin promoter driven-Cre). As controls, floxed 
TonEBP mice that did not express Cre recombinase were used (TonEBP fl/fl; WT). Both WT and AKO 
mice were fed a HFD for up to 12 weeks, starting at 8 weeks of age. The AKO mice were resistant to 
the development of obesity and showed lower fasting glucose levels than WT mice, with no difference 
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in food intake (Fig. 3-20a). In addition, the AKO mice demonstrated higher O2 consumption and CO2 
production rates (Fig. 3-20b and c) and generated more heat (Fig. 3-20d), also illustrated by having a 
higher body temperature than controls (Fig. 3-20e), suggesting enhanced energy expenditure. These 
mice also showed higher mRNA expression of Adrb3 and thermogenic genes, such as UCP-1, in 
iWAT, similar to the expression profile identified in the haplo-deficient mice, when either HFD-fed 
(Fig. 3-20f) or cold-exposed (Fig. 3-20g). These data further confirm that an absence of TonEBP in 
adipocytes enhances thermogenic activity and beiging of WAT. 
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3-4. Discussion 
 
Adipose tissues have received a lot of attention since as it has become clear that adipocytes and 
macrophages in them are important integrators of diverse physiological pathways regulating systemic 
insulin sensitivity and energy homeostasis [26]. It is therefore urgently necessary to identify regulatory 
convergence points that can be therapeutic targets to improve insulin resistance and impaired energy 
homeostasis in obesity. 
Here, we report for the first time that TonEBP is a critical suppressor of thermogenesis and beiging 
in WAT. TonEBP expression is specifically increased in iWAT in response to HFD feeding. Moreover, 
genetic TonEBP deficiency increased expression of beige adipocyte markers and genes involved in 
thermogenesis in this tissue. In addition, TonEBP haplo-deficient mice were resistant to cold 
exposure, establishing TonEBP as a central regulator of WAT thermogenesis. 
Understanding the molecular basis of the functional plasticity of adipocytes in obesity is essential 
to identify novel biomarkers and therapeutic targets for the development of anti-obesity and anti-
diabetic drugs. Although altered DNA methylation patterns are associated with adipocyte 
differentiation and obesity, the significance and exact molecular mechanisms involved in these have 
not been identified. Our findings show that the effect of TonEBP deficiency on the beiging of white 
adipocytes is mediated in part through suppression of Adrb3 expression by DNMT1-induced DNA 
methylation. TonEBP deficiency promotes chromatin opening and recruitment of RNA polymerase II 
through a reduction in DNA methylation in the Adrb3 promoter region. There is growing evidence for 
an involvement of epigenetic mechanisms in the development of complex diseases like obesity and 
type 2 diabetes [30, 31]. Thus, elucidating the role and mechanisms involved in DNA methylation is 
important to enhance understanding of obesity, considering the crucial role of the former in gene 
expression and chromatin architecture. In particular, DNA methylation provides a tissue-specific gene 
regulatory system, capable of controlling transcription factor accessibility and the recruitment of co-
repressors or co-activators to chromatin. Indeed, a previous study demonstrated that TonEBP acts as a 
transcriptional repressor of adipocyte differentiation by blocking epigenetic transition [14]. 
miRNAs showed regulatory roles in many biological processes including fat metabolism, adipocyte 
differentiation and insulin action associated with obesity and type 2 diabetes [27, 28]. Recent studies 
show that miRNA expression is dysregulated in obese adipose tissue [29]. The miR-30 family are 
potent regulators of thermogenesis and beiging of WAT [22]. Interestingly, we found that 
independently reducing expression of miR-30b and miR-30c increased the expression of TonEBP, 
indicating that TonEBP is a target of both miR-30b and miR-30c. Our data suggest that suppression of 
TonEBP is an important mechanism whereby miR-30b and miR-30c regulate thermogenic gene 
expression. 
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In summary, we identified a new transcriptional regulator, TonEBP, which is capable of 
simultaneously regulating multiple processes including inflammation and thermogenesis, and thus 
regulating adiposity and energy homeostasis. The importance of this mechanism is further highlighted 
by the extremely low expression of TonEBP in WAT from lean mice and the higher TonEBP 
expression in obese mice, implying a central role for TonEBP in the promotion of insulin resistance 
and obesity (Fig. 3-14). The phenotypes generated by ablation of TonEBP suggest that TonEBP has a 
potent cell-autonomous effect to inhibit WAT beiging and insulin resistance. Our findings imply that 
TonEBP is an excellent candidate drug target for the stimulation of beiging in WAT during obesity, 
and may therefore be utilized to design future therapeutics for the treatment of obesity, type 2 
diabetes, and other diseases characterized by insulin resistance. 
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Figure 3-1. TonEBP mRNA expression in metabolic tissues. 
TonEBP mRNA levels in eWAT, iWAT, BAT, muscle, and liver from C57BL/6J mice (n = 5–7 mice 
per group). Data (mean + s.e.m.) are representative of three independent experiments.  
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Figure 3-2. Adipocyte TonEBP expression was induced in obesity 
(a) TonEBP mRNA levels in eWAT, iWAT, BAT, muscle, and liver from C57BL/6J mice fed a NC or a 
HFD (n = 5–7 mice per group). (b) TonEBP protein level in iWAT and eWAT. (c) TonEBP mRNA 
levels in iWAT from C57BL/6J mice on +/db or db/db (n = 5–7 mice per group). (d) Thermogenic 
genes and (e) beige marker genes mRNA level in iWAT from C57BL/6J mice fed a NC or a HFD (n = 
5–7 mice per group). (f) Correlation of human adipocyte TONEBP mRNA level in subcutaneous fat 
from Saudi Arabian people with a range of BMIs (n = 15). All data are representative of four 
independent experiments and presented as mean + s.e.m. * p < 0.05 vs. HFD or db/db determined 
using Student’s t test. 
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Figure 3-3. TonEBP haplo-deficient mice resist the development of obesity 
(a) Body weights of male WT (TonEBP +/+) and TonEBP haplo-insufficient (TonEBP +/Δ) mice on a 
C57BL/6 background, fed either a NC or a HFD (n = 7–10 mice per group). (b) Representative 
photographs of HFD-fed TonEBP +/+ and +/Δ mice. (c) Food intake was measured in TonEBP haplo-
deficient mice fed with HFD (n = 5–7 mice per group). (d) Body composition and length of HFD-fed 
male TonEBP +/+ and +/Δ mice determined by echo MRI (n = 8 mice per group). (e) Representative 
photographs and weights of fat pads (epididymal, inguinal, and dorsal). All data are representative of 
four independent experiments and presented as mean + s.e.m. * p < 0.05 vs. TonEBP +/+, determined 
using Student’s t test. 
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Figure 3-4. TonEBP deficiency protects obesity in db/db mice 
(a) Body weight of male WT (TonEBP +/+) and TonEBP haplo-insufficient (TonEBP +/Δ) mice on a 
C57BL/6 background on +/db or db/db (n = 7–10 mice per group). (b) Weights of fat pads. All data 
are representative of two independent experiments and presented as mean + s.e.m. # p < 0.05 vs. +/db 
and * p < 0.05 vs. TonEBP +/+, determined using Student’s t test 
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Figure 3-5. TonEBP deficiency promotes energy expenditure  
(a-c) (a)VO2, (b) VCO2, and (c) heat production analyzed by indirect calorimetry in HFD-fed TonEBP 
+/+ and +/Δ mice (n = 6 mice per group). (d and e) Rectal temperature (temp) measured in NC-fed 
TonEBP +/+ and +/Δ mice at (d) room temperature and after (e) cold exposure (4°C) (n = 6 mice per 
group). All data are representative of three independent experiments and presented as mean + s.e.m. * 
p < 0.05 vs. TonEBP +/+ determined by Student’s t test. 
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Figure 3-6. TonEBP deficiency enhances thermogenesis and beiging of WAT 
(a and b) (a) Thermogenic gene and (b) beiging marker gene mRNA expression in iWAT of HFD-fed 
TonEBP +/+ or +/Δ mice (n = 6 mice per group). (c) Thermogenic gene mRNA (left) and UCP-1 
protein level (right) in iWAT of TonEBP +/+ or +/Δ mice exposed to cold (4°C) (n = 10 mice per 
group). (d) Representative images of H&E and UCP-1 stained iWAT from WT or TonEBP haplo-
deficient TonEBP mice exposed to cold (4°C). (e) Thermogenic gene mRNA levels in primary 
adipocytes differentiated from the stromal vascular fraction of TonEBP +/+ or +/Δ mice (n = 4). All 
data are presented as mean + s.e.m. * p < 0.05 vs. TonEBP +/+ determined by Student’s t test. 
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Figure 3-7. Effects of TonEBP knockdown or overexpression on thermogenic gene expression in 
3T3-L1 cells 
(a) Thermogenic gene mRNA on siRNA-mediated TonEBP knockdown (siTonEBP) and (b) 
adenovirus-mediated TonEBP overexpression (AdTonEBP) in 3T3-L1 stimulated with or without 
isoproterenol (Iso) (n = 4). All data are representative of four independent experiments and presented 
as the mean + s.d. *p<0.05 vs. scr siRNA or Ad-Empty determined by Student’s t test. 
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Figure 3-8. TonEBP deficiency ameliorates obesity-induced insulin resistance  
(a) Fasting blood glucose level in serum from HFD-fed TonEBP +/+ and +/Δ mice (n = 7–10 mice 
per group). (b) Glucose tolerance (left) and insulin tolerance (right) test data for TonEBP +/+ and +/Δ 
mice after 9 weeks of HFD feeding. (c) Fasting blood glucose (left) and insulin (right) level in serum 
from HFD-fed TonEBP +/+ and +/Δ mice. (d) Fasting blood glucose level of male TonEBP +/+ and 
TonEBP haplo-insufficient TonEBP +/Δ mice on a C57BL/6 background on +/db or db/db (n = 7–10 
mice per group). (e) Phosphorylation of AKT in eWAT and liver after insulin injection. All data are 
representative of two or three independent experiments and presented as mean + s.e.m. # p < 0.05 vs. 
NC or +/db, * p < 0.05 vs. TonEBP +/+ determined by Student’s t test. 
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Figure 3-9. TonEBP deficiency ameliorates obesity-induced metabolic dysfunction 
(a and b) (a) Serum concentration and iWAT mRNA expression of adiponectin and (b) leptin in 
TonEBP +/+ and +/Δ mice fed a HFD. (c and d) (c)Representative images of H&E stained sections of 
BAT and iWAT and (d) H&E staining and F4/80 immunostaining of eWAT from TonEBP +/+ and +/Δ 
mice fed a HFD. (e) F4/80 and TNFα mRNA levels in eWAT from HFD-fed TonEBP +/+ and +/Δ 
mice (n = 7–10). (f) Adipocyte function related genes mRNA levels in iWAT from C57BL/6J mice fed 
a NC or a HFD (n = 5–7 mice per group). (g) mRNA levels of adipocyte function related gene in 
eWAT from HFD-fed TonEBP +/+ and +/Δ mice (n = 7–10). All data are representative of three 
independent experiments and presented as mean + s.e.m. # p < 0.05 vs. NC, * p < 0.05 vs. TonEBP 
+/+ or NC determined by Student’s t test. 
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Figure 3-10. TonEBP deficiency protects fatty liver in obesity 
(a) Representative images and mass of liver from HFD-fed TonEBP +/+ and +/Δ mice. (b) Weight of 
liver of male TonEBP +/+ and TonEBP +/Δ mice on a C57BL/6 background on +/db or db/db (n = 7–
10 mice per group). (c) Representative images of H&E stained sections of liver from TonEBP +/+ and 
+/Δ mice fed with a HFD. (d) ALT concentration in serum from TonEBP +/+ and +/Δ mice fed a 
HFD. All data are representative of four independent experiments and presented as mean + s.e.m. # p 
< 0.05 vs. NC, TonEBP +/+ * p < 0.05 vs. TonEBP +/+ determined by Student’s t test. 
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Figure 3-11. TonEBP deficiency ameliorates obesity-induced hyperlipidemia 
Cholesterol (total and LDL), triglyceride, and free fatty acid levels, in serum from TonEBP +/+ and 
+/Δ mice fed a HFD. All data are presented as mean + s.e.m. # p < 0.05 vs. NC, TonEBP +/+ * p < 
0.05 vs. TonEBP +/+ determined by Student’s t test. 
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Figure 3-12. TonEBP suppresses Adrb3 gene expression 
(a) Adrb3 mRNA level in iWAT from TonEBP +/+ and +/Δ mice fed with a HFD. (b) Adrb3 
immunostaining in iWAT from TonEBP +/+ and +/Δ mice exposed to cold (4°C) (n = 8–10). (c) 
Adrb3 mRNA level in primary adipocytes from TonEBP +/+ and +/Δ mice (n = 4). (d) Adrb3 mRNA 
in 3T3-L1 adipocytes with siRNA-mediated TonEBP knockdown (TonEBP siRNA) or (e) adenovirus-
mediated TonEBP overexpression (Ad-TonEBP) (n = 4). All data are representative of three 
independent experiments and presented as the mean + s.e.m. # p<0.05 vs. NC or Con * p < 0.05 vs. 
TonEBP +/+ or scr siRNA or Ad-Empty determined by Student’s t test. 
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Figure 3-13. TonEBP suppresses Adrb3 promoter activity by binding to TonE element 
(a) Schematic representation of Adrb3 promoter region, including the TonEBP binding element. (b) 
Luciferase reporter assay for Adrb3 promoter in 3T3-L1 adipocytes subjected to siRNA-mediated 
TonEBP knockdown (TonEBP siRNA) (n = 4). (c and d) TonEBP binding to the putative TonEBP 
binding site in the Adrb3 promoter using (c) EMSA and (d) ChIP assay. All data are representative of 
four independent experiments and presented as the mean + s.d. #p<0.05 vs. NC, * p < 0.05 vs. scr 
siRNA determined by Student’s t test. 
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Figure 3-14. TonEBP promotes DNA methylation on Adrb3 promoter 
(a and b) (a) Chromatin accessibility, and (b) ChIP assay for RNA polymerase II (Pol II), on the Adrb3 
promoter region of 3T3-L1 adipocytes subjected to siRNA-mediated TonEBP knockdown. 
(c and d) DNA methylation analysis of the Adrb3 promoter using bisulfite sequencing in (c) iWAT and 
(d) 3T3-L1 adipocytes. All data are representative of two independent experiments and presented as 
the mean + s.d. * p < 0.05 vs. scr siRNA determined by Student’s t test. 
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Figure 3-15. TonEBP recruits DNMT1 to Adrb3 promoter through the interaction 
(a) ChIP assay for DNMT1 on the Adrb3 promoter in 3T3-L1 adipocytes subjected to siRNA-
mediated TonEBP knockdown. (b) Immunoprecipitation for TonEBP to demonstrate the DNMT1 
interaction. All data are representative of two independent experiments. 
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Figure 3-16. DNMT inhibition protects HFD-induced obesity 
(a-d) (a) Body weight, (b) body composition by echo MRI, (c) fat pad mass (epididymal and 
inguinal), and (d) fasting blood glucose level in HFD-fed mice intraperitoneally injected with PBS 
(vehicle) or RG108 (12 mg/kg) (n = 5 mice per group). All data are representative of two independent 
experiments and presented as mean + s.e.m. * p < 0.05 vs. vehicle determined by Student’s t test. 
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Figure 3-17. DNMT inhibition enhances energy expenditure by inducing WAT beiging and 
Adrb3 expression 
(a-d) (a) VO2, (b) VCO2, (c) heat production, and (d) rectal temperature in mice injected with PBS or 
RG108. (e and f) (e) TonEBP, UCP-1, and Adrb3 mRNA, and H&E and (f) immunostaining for UCP-
1 and Adrb3, in iWAT from HFD-fed mice intraperitoneally injected with PBS or RG108. (g) 
TonEBP. UCP-1 and Adrb3 mRNA in 3T3-L1 adipocytes treated with RG108 for 24 h. All data are 
representative of two independent experiments and presented as mean + s.e.m. * p < 0.05 vs. vehicle 
determined by Student’s t test. 
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Figure 3-18. DNMT1 deficiency increases Adrb3 expression  
(a) TonEBP, UCP-1 and Adrb3 mRNA expression in DNMT1, DNMT3a, or DNMT3b siRNA-
transfected 3T3-L1 cells. (b) Adrb3 promoter activity in TonEBP- or DNMT1-silenced 3T3-L1 cells. 
All data are representative of three independent experiments and presented as mean + s.e.m. * p < 
0.05 vs. scr siRNA determined by Student’s t test. 
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Figure 3-19. TonEBP is a direct target of miR-30b and miR-30c.  
(a) Schematic representation of the complementary site of miR-30b and miR-30c on TonEBP 3’-UTR. 
(b) TonEBP mRNA and (c) thermogenic gene mRNA in 3T3-L1 adipocytes transfected with miR-NC, 
miR-30b or miR-30c (n = 4). All data are representative of three independent experiments and 
presented as mean + s.e.m. * p < 0.05 vs. miR-NC determined by Student’s t test. 
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Figure 3-20. Improved metabolic phenotype of adipocyte-specific TonEBP knockout mice 
(a) Body weight, fasting blood glucose, and food intake by adipocyte-specific TonEBP knockout mice 
(TonEBP fl/fl, AQ cre) and control mice (TonEBP fl/fl) fed with a HFD (n = 9–10 mice per group). (b-e) 
(b) VO2, (c) VCO2, (d) heat production, and (e) rectal temperature analyzed in adipocyte-specific 
TonEBP knockout mice and control mice fed with a HFD (n = 8 mice per group). (f-g) mRNA 
expression of thermogenic genes in iWAT from adipocyte-specific TonEBP knockout and control mice 
fed with a (f) HFD or (g) exposed to cold conditions. All data are representative of two independent 
experiments and presented as mean + s.e.m. * p < 0.05 vs. TonEBP fl/fl determined by Student’s t test. 
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Figure 3-21. Schematic model for the role of TonEBP in obesity 
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Conclusion 
 
Adipose tissues have been the target of intense investigation because of the emergence of obesity 
and type 2 diabetes as a serious public health problem. Adipocytes and macrophages in the adipose 
tissues are crucial integrators of various physiological pathways regulating whole-body glucose and 
energy homeostasis. One of the most reliable links between obesity and its complication is 
inflammation in the adipose tissues. Obesity induces low-grade inflammation in the adipose tissues, 
which in turn, causes systemic insulin resistance by inhibiting insulin signal transduction.  
Adipose tissues are also capable of transforming the chemical energy of fat into heat, thus 
preventing excessive fat accumulation, through the activity of specialized thermogenic adipocytes. In 
addition to the classical brown adipocytes that largely comprise brown adipose tissue, and which 
constitutively express thermogenic genes, ‘brown-like’ adipocytes, known as beige cells, are also 
present in white adipose tissues, and thermogenesis can be induced in these cells in response to 
sympathetic activation. Activation of the thermogenic gene program in brown or beige adipocytes 
increases systemic energy expenditure and can ameliorate or prevent the development of obesity-
associated metabolic disorders as a result. Thus, efforts aimed at gaining a deeper understanding of 
the regulation of energy storage, mobilization, and use by adipocytes may lead to the identification of 
potential future therapies for metabolic disease. 
 
In this study, I discovered that TonEBP is a critical regulator of inflammation and the beiging 
process of WAT:  
1. I have investigated the role of macrophage TonEBP in inflammation and insulin resistance. I find 
that TonEBP is required for the recruitment of p300 to NFĸB in M1 macrophage activation and 
inflammation. In addition, I find that cerulenin is a powerful inhibitor of NFκB with minimal toxicity 
due to the disruption of the p300 recruitment to NFκB without affecting its nuclear localization or 
phosphorylation. In addition, TonEBP represses M2 polarization of macrophages via the suppression 
of PPARγ expression. Consistent with the dual regulation of M1/M2 polarization by TonEBP, myeloid 
specific-TonEBP deficient mice fed with high fat diet showed improved insulin resistance without 
changes in body weight. Their adipose tissues contain fewer M1 macrophages and more M2 
macrophages leading to reduced adipose inflammation. These findings reveal the functions of 
macrophage TonEBP to promote insulin resistance through the regulations of both NFκB activity 
(stimulation) and PPARγ expression (suppression). 
2. I have also investigated the TonEBP actions in adipocytes. In mice, TonEBP expression is 
specifically increased in eWAT and iWAT in response to feeding with HFD. Moreover, genetic 
TonEBP deficiency in adipocytes causes lower body weight and improved insulin resistance with 
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higher energy expenditure. Their white adipose tissue has elevated thermogenic activity and beiging 
phenotype with multi-locular lipid droplets and expression of UCP1 in iWAT. In addition, TonEBP 
haplo-deficient mice were resistant to hypothermia in response to cold exposure. These observations 
demonstrate that TonEBP is a key regulator (suppressor) of WAT thermogenesis and beiging. 
In sum, I have discovered that TonEBP regulates multiple processes including inflammation and 
thermogenesis and beiging of WAT. Elevated expression of TonEBP in adipose tissue including 
macrophage and adipocyte of obese mice promotes insulin resistance and obesity (see graphical 
summary below). These findings raise the possibility that TonEBP is an attractive target for future 
therapeutics in the treatment of obesity and type 2 diabetes. 
 
 
 
Graphical summary 
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처음 유니스트 대학원에 진학하면서 졸업은 까마득히 멀고 먼 미래의 일이라 
느꼈었습니다. 그러나 석박사 통합과정 5 년이 지난 지금 학위 논문을 마무리 하고 있는 
제 자신을 보면 꿈만 같습니다. 처음 실험실에 들어왔을 때, 아무 것도 몰랐던 제가 
박사학위를 마치기까지는 지도교수님이신 권혁무 교수님께서 계셨기에 가능했습니다. 
바쁘신 중에도 연구뿐만 아니라 연구자에게 필요한 다양한 부분들에 대해 꼼꼼하게 
지도를 해주시고, 항상 조급해하지도 느슨해지지도 않고 일관되도록 이끌어 주셔서 
졸업이 가능했었던 것 같습니다. 또한, 오랜 학위기간 동안 지치지 않고 열정을 가지고 
열심히 할 수 있도록 저를 신뢰해주시고 하고자 하는 연구들을 지원해주신 존경하는 
교수님께 정말 감사 드립니다. 교수님의 가르침을 바탕으로 앞으로 좋은 연구자가 될 수 
있도록 노력하겠습니다. 그리고 바쁘신 시간 내주시어 학위 논문을 잘 마무리 할 수 
있도록 지도해주신 강병헌 교수님, 고명곤 교수님, 박지영교수님, 최장현 교수님께도 
감사의 말씀을 전합니다. 이외에도 학위과정 동안 도와주신 이창욱교수님, 이화선교수님, 
생명과학부 모든 교수님들께 감사합니다. 
또한, 박사 학위기간 동안 교수님만큼 저를 제자로 생각해주시고 많은 가르침과 도움을 
주신 최수연 박사님께도 깊은 감사의 말씀을 드립니다. 실험실 생활을 같이하면서 항상 
선배로서 모범을 보여준 은진이 누나와 후배로서 불평 한마디 없이 잘 따라준 현제, 
준호, 병진이형, 승민이, 규원이, 현이, 그리고 연구에만 집중 할 수 있도록 도와준 
나리선생님 등 많은 분들의 도움이 있었기에 학위를 잘 마무리 할 수 있었습니다. 연구 
과정에서 혼자라면 할 수 없었던 많은 실험들을 도와준 병진이형, 준호, 승민이를 포함한 
IKD 실험실 구성원 모두에게 감사의 말씀을 드립니다. 
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학교 밖에서도 가장 큰 힘이 되어준 가족들에도 고마움을 전합니다. 오랜 시간 멀리 
떨어져서 매일 걱정해주시고 격려해주시고 지원해주시고 응원해주신 부모님, 목표를 
향해 열심히 나아가고 있는 기특한 한별이, 집에 갈 때마다 반갑게 맞아주고 오빠 
장난도 다 받아주는 지은이 덕분에 모든 과정을 마칠 수 있었습니다. 뿐만 아니라 항상 
먼 곳에서도 응원해주시는 할머니, 외할머니, 할아버지, 살아 생전에 항상 저를 
자랑스러워 해주신 외할아버지를 포함한 가족 분들께 감사합니다. 
언급하지 못하였으나 학위과정 동안 도와주신 많은 분들께도 감사의 마음을 표하며, 
앞으로 더욱 열심히 연구에 정진하여 발전하는 모습을 보여드리겠습니다. 감사합니다. 
